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Abstract 
E and Id proteins are members of the basic helix-loop-helix (bHLH) transcription 
regulator family. These proteins control a broad range of lymphocyte biology, from the 
development of multiple lineages to execution of their effector functions. With the 
development of new experiment models, novel functions of E and Id proteins continued 
to be discovered. In this thesis, I focused my study on the role of Id2 in γδ T cells and 
CD4+ αβ T cells, as well as the role of Id3 in B cells. 
Id proteins have been shown to control γδ T cell development. Id3 knockout 
mice demonstrate a dramatic expansion of innate-like Vγ1.1+ Vδ6.3+ γδ T cells in the 
neonatal stage, suggesting that Id3 is an inhibitor of their development. Interestingly, 
Id3 knockout mice with a B6/129 mix background have much less expansion of the 
Vγ1.1+ Vδ6.3+ γδ T cells compared to mice with pure B6 background. Genetic studies 
showed that this difference is strongly influences by a chromosome region very close to 
the Id2 locus. Using the Id2f/f CD4Cre+ mice, I found that Id2 is also an inhibitor of γδ T 
cell development. Deletion of Id2 alone is sufficient to enhance the maturation of these 
cells in the thymus and induce a moderate expansion of γδ T cells in the periphery. This 
study demonstrated the delicate balance of transcription control in cells of the immune 
system. 
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The Id2f/f CD4Cre+ mice also enabled me to study the role of Id2 in peripheral 
CD4+ αβ T cell functions, which was difficult in the past because Id2 knockout mice lack 
lymph node development. I found that CD4 T cells in these mice have a profound defect 
in mounting immune responses, demonstrated by a complete resistance to induction of 
experimental autoimmune encephalomyelitis (EAE). I found that Id2-deficient CD4 T 
cells fail to infiltrate the central nervous system, and the effector CD4 T cell population is 
smaller compared to that in control mice. Id2 is important for the survival and 
proliferation of effector CD4 T cells, and this phenotype was correlated with an 
increased expression of Bim and SOCS3. This study revealed a novel role of Id2 in the 
functioning of CD4+ αβ T cells. 
Switching my focus to B cells, recent next generation sequencing of human 
Burkitt’s lymphoma samples revealed that a significant proportion of them have 
mutations of Id3. This finding suggests that Id3 may be a tumor suppressor gene in the 
lymphoid system. Utilizing various Id3 knockout and conditional knockout mouse 
models, I showed that Id3 deficiency can accelerate lymphoid tumor genesis driven by 
the over-expression of oncogene c-Myc. This work may lead to development of a more 
realistic mouse model of human Burkitt’s lymphoma, allowing more mechanistic studies 
and perhaps preclinical tests of new therapies. 
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1. Overview 
The immune system is unique among the systems of the multi-cellular organism. 
Unlike other systems, which may be near mature at birth, the immune system continues 
to develop and adapt after the birth of the animal. However, all cells of the immune 
system develop and differentiate from the same hematopoietic stem cell (HSC) 
throughout the animal’s life span. The differentiation process, the formation of 
individual progeny clones, the execution of the effector functions, and the formation of 
immune memory are all tightly regulated, yet the system can still rapidly change to 
respond to environmental challenges and protect the organism. A delicate genetic 
network controls all of these processes, with surprisingly few but versatile genes capable 
of influencing both the development and response of immune cells. The E protein and Id 
protein transcription regulators are prime examples of such multi-functional regulators 
of the immune system (Kee, 2009). They are multifunctional genetic factors that play 
critical roles in the immune system starting from lymphocyte development as early as 
before birth to the generation of immune memories that may last decades. Research on 
these molecules revealed to us the complex architecture of the immune system, and this 
knowledge can instruct us on how to carefully develop therapies to manipulate the 
immune system for a variety of human diseases. 
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1.1 Introduction to E proteins and Id proteins 
E proteins and Id proteins are basic helix-loop-helix transcription regulators that 
have a broad impact on the immune system (Murre, 2005). In mammalian immune 
systems, there are three major E proteins (E2A, HEB, E2-2) and two major Id proteins 
(Id2, Id3) expressed by a variety of cell types. The E proteins can homo-dimerize or 
hetero-dimerize with their helix-loop-helix domains, and the dimers bind to DNA 
sequences containing the E-box (CANNTG) with their basic DNA binding domains. The 
sequence simplicity of E-box implies that a large number of genes may contain such 
sequences and be subject to E protein control. The binding of E protein can recruit 
transcription co-activator or co-repressor to the target gene and promote or repress its 
expression. On the other hand, the Id proteins also contain helix-loop-helix domains but 
not basic DNA binding domains. Therefore, Id proteins can sequester E proteins and 
prevent them from binding to target DNA, essentially functioning as E protein inhibitors. 
The E protein – Id protein interaction network is very adaptable during the 
development of immune cells as well as the development of the entire organism. The 
activity of E proteins is regulated by the expression level of individual E proteins and 
the inhibition from Id proteins. Different cell types have different levels of E protein 
activity and target gene preferences. Therefore, it is not surprising that this E – Id axis is 
involved in many different events in the immune system, including hematopoietic stem 
cell homeostasis and differentiation, the development of T and B lymphocyte, innate 
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lymphoid cell and plasmacytoid dendritic cell, the formation of lymph node,  peripheral 
T cell response, and hematopoietic cancer formation (Kee, 2009; Spits and Di Santo, 2011; 
Yang et al., 2011). Novel functions of the E – Id axis are continuing to be discovered. 
Below, the discussion will be focused on what is currently known about the role of E 
protein and Id protein in T lymphocyte development / function and lymphoid tumor 
formation, and how novel materials and methods may further advance our 
understanding of this transcription control system, especially about Id2 and Id3. 
1.2 E and Id in the Transcription Control of T Cell Development 
and Function 
T lymphocytes develop in the thymus and migrate to the peripheral lymphoid 
organs, where they interact with antigen presenting cells, become activated, and carry 
out their effector functions, such as killing infected cells or producing cytokines. E and 
Id proteins have been shown to be involved in many stages of T lymphocyte 
development and function, such as during the commitment to T cell lineage, αβ/γδ 
lineage choice, CD4/CD8 lineage choice, as well as during peripheral T cell homeostasis 
and function. 
1.2.1 Commitment to the T cell lineage 
In the bone marrow, the hematopoietic stem cells produce all the cell lineages of 
the hematopoietic system. Early in the differentiation process, the stem cells give rise to 
two different progenitors: one with potential to produce myeloid cells, such as 
neutrophils and eosinophils, and one with potential to produce lymphoid cells, such as 
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B cells and T cells. The lymphoid progenitor cells further differentiate into T cell 
progenitors and B cell progenitors, and the T cell progenitors leave the bone marrow 
and migrate to the thymus, where they continue their differentiation into mature T 
lymphocytes (Kindt et al., 2007). 
E proteins start to influence the development of T cells from the very beginning. 
The E2A-deficient HSCs produced reduced numbers of lymphoid-primed multipotent 
progenitor cells (LMPPs), and these cells have reduced potential to produce cells of the 
lymphoid lineage but instead tend to differentiate into granulocytes and macrophages 
(Dias et al., 2008a). E2A seems to cooperate with transcription factor PU.1 to generate a 
“lymphoid priming” effect in these progenitor cells and increase the expression of 
multiple genes unique to the lymphoid lineage, thus promoting the differentiation 
toward that lineage (Dias et al., 2008b). 
Once committed to the lymphoid lineage, E2A continue to play a crucial role in 
driving B cell development through activation of a cascade of B cell-specific 
transcription factors, including EBF1 and Pax5 (Hagman and Lukin, 2006). It has been 
proposed that cells which receive Notch signaling will instead adopt a T cell fate, at least 
partially through the antagonizing of E2A regulation on target genes by the Notch 
pathway (Tanigaki and Honjo, 2007). Interestingly, E2A itself can also up-regulate Notch 
expression, making the cells sensitive to Notch ligand signaling (Ikawa et al., 2006). In 
the absence of E2A, B cells fail to develop, but T cell numbers are also reduced, 
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indicating that E2A does not simply promote or repress the choice of differentiation into 
T cells, but it probably is involved in a more complicated network. 
The lymphoid progenitor that picks up the propensity to differentiate into the T 
cell lineage will migrate out of the bone marrow and into the thymus. In the thymus, the 
progenitors further differentiate into either cells that give rise to innate lymphoid cells 
(including NK cells, lymphoid tissue inducer cells, etc) or cells that give rise to T cells. 
Id2 is crucial at this step; its presence suppresses the E protein activity and allows the 
development of all innate lymphoid cells (Mjosberg et al., 2012). For those cells that do 
not up-regulate Id2 at this stage, they proceed down the path to become one of two 
kinds of T lymphocytes: αβ or γδ T cells. 
1.2.2 αβ/γδ lineage choice and γδ T cell development 
The early T cell progenitors do not express T cell markers such as CD4 or CD8, 
thus called double negative (DN) cells. Most DN thymocytes will eventually rearrange 
one of two families of T cell receptor genes: the αβ or the γδ receptor, and the fate of the 
cells will be determined by this event. Those which successfully rearrange the αβ 
receptor will become αβ T cells, while rearrangement of the γδ receptor leads to the γδ T 
cell fate. During fetal development and the neonatal life, most T cells adopt the γδ T cell 
fate, but as the animal matures, αβ T cells quickly become dominant, account for the 
majority of the thymic output in adults (Havran and Allison, 1988). How this transition 
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occurs, and what determines the αβ/γδ lineage choice, have long been fascinating 
questions to immunologists. 
Two different hypotheses have been proposed to explain how thymic progenitor 
cells make the lineage choice decision. The first is the “pre-commitment” model, stating 
that some progenitor cells express key transcription factors for the γδ lineage (such as 
SOX13) in a stochastic manner, and these cells are “committed” to become γδ T cells 
(Melichar et al., 2007). The rearranged T cell receptor type must match the pre-
commitment of the cell for it to continue its development. The other hypothesis 
emphasis the role of the T cell receptor produced in the rearrangement process. The 
“instructive model” states that the T cell receptor has a decisive role of instructing the 
fate of the cell, and this involves the E – Id axis. Proponents of this hypothesis observed 
that αβ and γδ T cell receptors possess certain different qualities, and these differences 
can determine the subsequent development of the cells. For example, the γδ T cell 
receptors have been shown to be generally capable of sending a stronger intracellular 
signal into the cell when compared with the TCRβ-pTα T cell receptors in the DN cells 
(Hayes et al., 2003). Such signal involves activation of the MAPK pathway, which can 
lead to up-regulation of one of the Id proteins, Id3, and inhibit the activity of E proteins 
(Lauritsen et al., 2009). The resulting difference in E protein-controlled transcription 
network may promote the cell to adopt a program specific to the γδ T cells, thus 
diverting the cells from the αβ T cell fate. 
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Once the cell picks the γδ T cell fate, it proceeds toward a different 
differentiation pathway from the rest of the αβ-destined T cells. The cell ceases to 
rearrange the β T cell receptor locus and does not rearrange the α locus. Instead, it starts 
to differentiate into effector-like cells. This is different from the αβ T cells, as the 
majority of αβ T cells retain a naïve phenotype in the thymus. The γδ T cells may 
differentiate into either IFNγ producing or IL-17 producing cells. It has been shown that 
if a developing γδ T cell encounters its cognate antigen in the thymus, it becomes an 
IFNγ producer, while those that do not encounter an antigen become IL-17 producers 
(Jensen et al., 2008). Unlike the αβ T cells, among which the ones that react with self 
antigens strongly will be negatively selected and deleted, autoreactive γδ T cells actually 
survive and migrate to the periphery. It is believed that these cells function as innate-like 
sensors of danger signals and respond rapidly to the release of self molecules in stressed 
tissue by producing inflammatory cytokines including IFNγ (Vantourout and Hayday, 
2013). On the other hand, the IL-17 producing cells do not receive TCR signaling from 
antigen in the thymus, and these cells also seem to be rapidly responding to non-TCR 
signaling, such as inflammatory cytokine signaling, in the periphery (Cai et al., 2011). 
They also respond to such stimulations promptly by pumping out more IL-17, 
contributing to tissue inflammation. There are also γδ T cells that respond to foreign 
antigen stimulation in a genuinely adaptive fashion; for example, phycoerythrin (PE) 
specific γδ T cells have been identified in both mouse and human, and these cells can 
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respond to PE stimulation through their γδ TCR without the aid of MHC presentation, 
become activate, expand and produce effector cytokines (Zeng et al., 2012). 
Another important distinction between αβ and γδ T cells is that γδ T cells 
produced at different developmental stages utilize special semi-invariant TCR V 
segments. In human, the first wave of γδ T cells produced during fetal development 
utilizes the Vδ2 segment and circulate in the blood, while the γδ T cells produced later 
during neonatal life utilize the Vδ1 segment and populate the mucosal surfaces and 
internal organs (Krangel et al., 1990; Pang et al., 2012). In mice, multiple waves of γδ T 
cells develop throughout embryonic development and early life, utilizing Vγ5, 6, 4 and 1 
segments sequentially (Carding and Egan, 2002). These different waves of cells migrate 
to specific target organs and reside there throughout the life span of the animal, largely 
maintained by homeostatic proliferation, with little further thymic output supply. How 
these TCR V segments are used in such a sequential and orderly manner, and how their 
usage eventually largely stops and be replaced by αβ T cells are interesting questions. 
For a certain subset, the skin-directed dendritic epithelial T cells (DETC), which utilize 
the Vγ5 segment (alternatively named Vγ3), a specific gene, skint1, has been identified to 
be essential for their development ((Boyden et al., 2008)). One may speculate that 
controlled expression of other genes may similarly dictate the timely development or 
selection of γδ T cells utilizing other V segments.
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Among these specific waves of γδ T cells, not all of them require a high level of 
Id3 to develop. In the absence of Id3, the development of certain subsets of γδ T cells 
actually is greatly enhanced. The rearrangement of γδ TCR genes, especially those 
involving the Vγ1.1, is enhanced in Id3 knockout mice (Ueda-Hayakawa et al., 2009), 
and the total number of γδ T cells expressing the Vγ1.1 and Vδ6.3 T cell receptor gene 
segments increases dramatically (Alonzo et al., 2010; Ueda-Hayakawa et al., 2009). How 
these cells are differently regulated from other γδ T cells, and how the E – Id axis 
influence their development will be the focus of Chapter 2.  
1.2.3 CD4/CD8 lineage choice and thymic selection 
For the majority of thymocytes that adopt the αβ T cell fate, they proceed from 
the DN stage into DP (double positive) stage, when they express both CD4 and CD8 on 
their surface. The cells rearranged their TCR β chain in the DN stage, and they rearrange 
their TCR α chain in the DP stage. In the DP stage, the cells again make a lineage choice 
to become either a CD4 single positive (SP) cell or a CD8 single positive cell. The SP cells 
are mature and ready to migrate to the periphery to carry out effector functions.  
The T cell receptor again plays a significant role in this decision. Cells expressing 
receptors capable of interacting with class I major histocompatibility (MHC) molecules 
go on to become CD8 SPs, while those with receptors binding class II MHCs become 
CD4 SPs. The TCR-MHC interaction also sustains the survival of the T cells, so the 
process is termed “positive selection”. Those that fail to interact with either class of 
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MHCs die through apoptosis, due to a lack of survival signal (death by neglect), and do 
not proceed to the next stage. However, how does a DP cell, which express both CD4 
and CD8, tell the difference between a TCR signal that is coming from class I or class II 
MHC molecules? Similar to the choice between αβ and γδ lineages, both instructive 
model and stochastic model have been proposed. The stochastic model suggests that DP 
cells will randomly down-regulate either CD4 or CD8; because CD4 and CD8 are 
important for stabilizing the interaction between MHC and TCR, a T cell with a TCR 
binding to class II MHC will only keep receiving signals and survive if it down-regulates 
CD8 and keeps CD4, and the opposite is true for T cells recognizing class I MHC (Chan 
et al., 1994). The instructive model (Singer et al., 2008), on the other hand, suggests that 
there are qualitative difference between TCRs recognizing class I and class II MHCs. Dr. 
Alfred Singer’s lab observed that the downstream signal is typically stronger from an 
interaction between CD4, TCRs and class II MHC molecules, and they found that DP 
cells go through an intermediate stage when they down-regulate CD8 and become 
CD8lowCD4+ cells. At this stage, T cells that express TCRs recognizing class II MHC 
molecules maintain their interaction with the help of CD4, while those that express TCRs 
recognizing class I MHC molecules lose their TCR signal, at the same time gaining IL-7 
receptor expression and receiving IL-7 signal (Brugnera et al., 2000). These differences 
lead to either maintenance of CD4 expression, or a switch to CD8 expression, generating 
CD8 SP and CD4 SP cells, respectively. 
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The CD4/CD8 lineage choices, as well as the DP survival check point, again are 
both involving the E – Id axis. When the DP thymocytes successfully rearrange the 
TCRα gene and express the αβ TCR on the surface, and the receptors interact with one 
of the MHC molecules, again a signal will be sent into the cell. This signal again can up-
regulate Id3 expression and inhibit the activity of E proteins, thus permitting the cells to 
pass through the “check point” and change the transcription program to one of the SP 
cells (Engel et al., 2001). If the two major E proteins, E2A and HEB, are both deleted in 
the DP thymocytes, the cells may proceed to become SP cells even without a successfully 
rearranged T cell receptor, partially eliminating the requirement of positive selection 
(Jones and Zhuang, 2007). 
However, in the aforementioned experiment, all the TCR-negative “SP” cells 
express CD8, and no CD4 SP cells are formed. This indicates that the E – Id axis also 
influences the CD4/CD8 lineage choice. The opposite mouse model, with deletion of 
both Id3 and Id2 in DP cells, results in no TCR-negative SP cells, and all SP cells thus 
formed are CD4 SP (Jones-Mason et al., 2012). This indicates that higher E protein 
activity is important for the CD4 SP fate, while the lack of it is compatible with the CD8 
SP fate. The effect may be mediated by the E protein suppression of IL-7 receptor α 
expression. It is mentioned above that CD8 SP differentiation requires IL-7 signaling. 
When Id2 and Id3 are deleted, E protein activity becomes too high, and IL-7 receptor α 
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expression decrease; this situation can be inhibitory to CD8 SP cell development (Jones-
Mason et al., 2012). 
Before the mature SP cells leave the thymus, a final check point they must pass is 
the negative selection. Cells that are strongly reactive to self antigens will be deleted, 
thus preventing the formation of autoimmunity. The medullary thymic epithelial cells 
(mTECs) express a special transcription factor AIRE that can induce nonspecific 
expression of tissue antigens on their surface, therefore enabling the screening of T cells 
reactive against different tissues (Metzger and Anderson, 2011). In at least one case, this 
negative selection also involves Id3. In the Id3 deficient male mice, T cells specific for the 
male antigen H-Y are not deleted and can migrate to the periphery (Rivera et al., 2000). 
This may be explained by Id3 mediating downstream signaling of the TCR; in the 
absence of Id3, the TCR signal strength is generally weakened, so cells that normally die 
because of strong TCR interaction with self antigen now survive. The E – Id axis is 
indeed important for the development of T lymphocytes from the beginning to the end. 
1.2.4 Peripheral T cell homeostasis and function 
The T cells that have successfully gone through all the differentiation processes 
and check points eventually leave the thymus and migrate into the periphery. These 
cells circulate throughout the body in a naïve, quiescent state, surveying the antigen 
presenting cells in the body constantly. If a naïve T cell encounters its cognate antigen, 
such as an antigen from an infectious agent, the T cell can become activated and 
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proliferate vigorously to form a large population of effector T cells to carry out immune 
defense functions, such as killing infected cells or secreting cytokines. If the infection is 
cleared, most effector T cells will die by apoptosis, and only a small population of cells 
will survive and become long-lived memory cells. If the same antigen is encountered 
again, the memory cells can re-activate and mount a secondary immune response much 
faster and stronger than the primary immune response, thus offering the host a superior 
level of protection. 
No other mammalian tissue is regulated the same way as the lymphocytes. A 
large pool of diverse naïve lymphocytes are maintained for a long time with little 
apparent change; upon challenge, a very selective subset must burst into proliferation 
quickly; once the challenge is gone, the majority of the effectors must die, and memory 
cells must survive, sometimes for a very long period of time. This is in stark contrast to 
the epithelial cells, which basically are renewed consistently at a steady speed, or to the 
neurons, which basically don’t proliferate much after birth. The lymphocytes must have 
an extraordinarily flexible population size control mechanism. 
The overall “theme” of lymphocyte population control mechanism may be 
summarized as the following: “die unless instructed otherwise, plus always be ready to 
proliferate.” Just like in the thymus, T cells that do not receive survival signals, such as 
when isolated in in vitro culture, very quickly die. The naïve T cells require constant low 
level stimulation to their T cell receptors (TCRs) from MHCs loaded with self peptides to 
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maintain their survival (Surh and Sprent, 2008). They also require IL-7, which is 
produced by various tissues, including fibroblastic reticular cells in the T cell zones of 
secondary lymphoid organs (Link et al., 2007). These signals are important for the 
continuous expression of anti-apoptotic proteins, such as Bcl-2 and Mcl-1, to keep the 
cells from dying (Khaled and Durum, 2002). If a T cell encounters its cognate antigen, 
the peptide-MHC interaction with the TCR is typically stronger, and second and third 
signals provided by co-stimulatory molecules (such as CD80 and CD86) and cytokines 
(such as IL-2) together can activate the survival and proliferation program in the 
lymphocyte. As long as these signals persist, the T cell can continue to survive and 
proliferate, with the exception of chronic infections, in which situation the T cell 
response may be dysregulated or dampened. During an immune response, multiple 
transcription factors capable of driving cell growth and proliferation will be turned on, 
such as c-Myc and AP-1 transcription factors (Hayashi and Altman, 2007; Yang and Chi, 
2012). But activated cells are also highly susceptible to cell death. Activated T cells 
increase expression of Fas ligand, which when ligating to Fas expressed on other T cells 
can induce the T cells to go through apoptosis (Green et al., 2003). Yet the subset of T 
cells that become memory cells is different. They are less proliferative and produce less 
effector molecules, but they are also less susceptible to cell death. Even when the antigen 
is cleared and the TCR stimulation ceases, the memory T cells can continue to survive. 
These cells now require less of the signal from self peptide-loaded MHC molecules, but 
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they gain the responsiveness to IL-15, in addition to IL-7 (Surh and Sprent, 2008). They 
also gain a low level of turn over capability, replenishing their numbers by slow 
proliferation (Tough and Sprent, 1995). 
The research of T cell homeostasis is currently ongoing in several directions. One 
of the active fields is the differentiation of effector cells versus memory cells. Which 5% 
of the total T cells formed in an immune response are going to become memory T cells? 
There are three different possible mechanisms (Amsen et al., 2013). The first theory 
suggests there are pre-committed populations of T cells at the very beginning of an 
immune response. The cells that receive different signals when they are activated are 
pre-destined to become either effector or memory T cells. The second theory argues 
against such a pre-commitment; instead, it postulates that all cells have equal potential 
of becoming memory, and through competition or random chance, only a small 
proportion of the cells receive sufficient survival signals and persist. A third theory is 
poised between the previous two, suggesting that in the early phase of an immune 
response, the majority of the cells produced become effector cells, while in the later stage, 
when the triggering pathogen is cleared and inflammation is subsiding, the T cells 
receive less vigorous stimulation and are more prone to become memory cells. Each 
theory has its own supporting experiment evidence. It is possible that the formation of 
memory is a fine-tuned phenomenon and is slightly different in different immune 
responses, and in some cases it is more predestined, while in others the effectors are less 
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terminally differentiated and retain memory potential. In fact, the memory T cells are 
known to be a heterogeneous population. The so called “effector memory cells” have 
phenotypes of effector T cells, patrol the mucosal surfaces, can produce effector 
molecules like cytokines rapidly, have a long life span but do not proliferate much. On 
the other hand, the “central memory cells” are more similar to naïve T cells, reside in the 
secondary lymphoid organs, do not produce effector molecules, live long and can 
proliferate and differentiate into new effector cells. The effector memory cells are 
considered to provide more direct protection for the host, while the central memory cells 
are crucial in forming the secondary immune response. Recently, a population of 
“memory stem cells” was identified to be the progenitor of both effector memory and 
central memory cells (Gattinoni et al., 2009). This rare population of cells has a gene 
expression profile that is similar to quiescent naïve T cells and can confer even better 
protection to a recipient of the cells than the other two types of memory cells in a 
transfer experiment. How all these populations differentiate and are maintained is an 
active area of research, for the knowledge is potentially useful for the design of vaccine 
strategies. 
The differentiation and maintenance of CD4 T cells versus CD8 T cells appear to 
follow different mechanisms. A very significant difference is that CD4 memory T cells 
appear to decline over time (Homann et al., 2001). This may be caused by their relatively 
low expression of CD122, which is the receptor of IL-2 and IL-15; therefore, they cannot 
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compete with the CD122hi memory CD8 T cells and NK cells for cytokine support for 
survival (Purton et al., 2007). Another possibility is they are constantly being replaced by 
CD4 T cells that have TCRs with higher affinity for either the foreign antigen or self 
antigen, so the observed memory population does not persist (Williams et al., 2008). 
While the formation of CD8 memory T cells requires help from CD4 T cells, it has been 
shown that the formation of CD4 memory T cells may require help from B cells (Pepper 
and Jenkins, 2011). Naïve CD4 T cells also require a longer period of stimulation than 
CD8 T cells to undergo efficient differentiation into memory cells (Williams et al., 2008). 
These factors may all contribute to the difference between CD4 and CD8 memory T cell 
maintenance. Nevertheless, both populations require IL-7 and IL-15 to survive and 
turnover. 
E proteins and Id proteins also have roles in the population size control of 
peripheral T lymphocytes, including all the naïve, effector and memory populations. 
Unlike double deletion of Id2 and Id3, loss of Id3 alone allows development of CD4 and 
CD8 SP cells, but the deletion results in a loss of the naïve phenotype, i.e., the mature T 
cells can spontaneously become activated (Miyazaki et al., 2011). Without Id3, the 
unrestrained T cells can adopt an effector-memory phenotype right in the thymus and 
even induce B cell follicle formation (Miyazaki et al., 2011). Id3-deficient CD4 T cells also 
have reduced potential to develop into regulatory T cells but higher potential to become 
pro-inflammatory Th17 cells (Maruyama et al., 2011). Combined with a thymic defect of 
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negative selection in Id3 knockout mice (Rivera et al., 2000), these phenomena of 
enhanced activation and inflammation may contribute to the spontaneous development 
of Sjogren syndrome, an autoimmune destruction of exocrine gland, in the Id3-deficient 
mice (Li et al., 2004). However, Id3 is also important for the formation of memory T cells. 
Two reports showed that Id3 supports the survival of effector and memory CD8 T cells 
following virus and bacteria infections (Ji et al., 2011; Yang et al., 2011). 
Single deletion of Id2 results in a milder phenotype in mature T lymphocytes in 
the steady state, with largely normal numbers of CD4 and CD8 T cells in the periphery. 
However, the importance of Id2 is demonstrated when the cells are activated. Id2-
deficient CD8 T cells form a smaller pool of effector cells in a Listeria monocytogenes 
infection model, and these cells form a smaller number of memory cells, especially 
decimating the effector memory cells (Cannarile et al., 2006).  How Id2 functions in the 
CD4 T cell immune responses is less well studied, and this will be the focus of 
discussion in Chapter 3. 
1.3 E and Id in the Development of Lymphoid Tumors 
Considering the complexity of regulations in the development of the lymphoid 
system, and the explosive proliferation potential of the lymphocytes, it is not surprising 
that many different kinds of human and mouse malignancies arise from the lymphoid 
system. Cancer can develop from cells of almost any stage of development. The surface 
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markers they express can indicate their origin, serve as diagnostic standards, and 
sometimes even hint at their behavior and potential clinical prognosis. 
Human malignancies of lymphoid cells can be largely divided into leukemias 
(those involving bone marrow and blood) and lymphomas (those forming solid tumors), 
although sometimes the lymphomas can also progress into leukemias. Most common 
malignancies belong to either the T cell type or the B cell type, with B cells accounting 
for the majority of cases (Fig 1 and Fig 2) (Longo, 2011). The malignancies arising from 
the early progenitor cells typically present as acute leukemias, flooding the patient’s 
bone marrow and blood with blasts, while those arising from mature, peripheral 
populations often behave more indolently, sometimes remaining asymptomatic for 
decades. However, this distinction is by no means absolute, and the apparent stage of 
differentiation of the cancer cells does not directly indicate the stage at which the cells 
acquired their genetic changes and became transformed. 
A distinctive feature of the lymphoid malignancy is that many of them have 
recurrent genetic abnormalities, including chromosome translocations, that can be 
causally linked to the malignant transformation process (Longo, 2011). Such clear 
mechanisms of transformation are unique and not frequently seen in tumors of other 
organ systems. Many such events involve translocation of chromosomes bring proto-
oncogenes to the immunoglobulin genes (in B cells) or the T cell antigen receptor genes  
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Figure 1: Human B cell lymphomas and their approximate relationship to 
normal B cell differentiation 
ALL, acute lymphoid leukemia; CLL, chronic lymphoid leukemia; SL, small 
lymphocytic lymphoma. Adapted from: Chapter 110. Malignancies of Lymphoid Cells. 
Harrison's Principles of Internal Medicine, 18e, 2011. 
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Figure 2: Human T cell lymphomas and their approximate relationship to 
normal T cell differentiation 
ALL, acute lymphoid leukemia; T-ALL, T cell ALL; T-LL, T cell lymphoblastic 
lymphoma; T-CLL, T cell chronic lymphoid leukemia; CTCL, cutaneous T cell 
lymphoma; NHL, non-Hodgkin's lymphoma. Adapted from: Chapter 110. Malignancies 
of Lymphoid Cells. Harrison's Principles of Internal Medicine, 18e, 2011. 
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(in T cells). Rearrangement of these antigen receptor genes during lymphocyte 
development makes them frequent targets of chromosome translocation, and their 
strong expression in the individual lineages can boost the expression of proto-oncogenes 
translocated to their proximity. Other than translocations, gene deletion or amplification, 
as well as mutation, also contribute to the transformation of different types of lymphoid 
cancers. Some of the oncogenes control cell death or proliferation, while others are 
transcription factors capable of disrupting lymphocyte differentiation when 
inappropriately expressed. Again, E proteins and Id proteins are also involved in this 
process. 
The peripheral CD8 T cell study mentioned above demonstrated that a proper 
balance between E proteins and Id proteins is not only essential for developing 
lymphocytes to progress through the differentiation processes, but it is also critical for 
controlling the cell population size at each stage. In fact, early studies of E2A knockout 
mice showed that these mice can develop a very aggressive T cell lymphoma (Bain et al., 
1997; Yan et al., 1997). Human study also found that E2A is often lost in cancer cells 
from patients with Sezary syndrome, a type of peripheral T cell lymphoma (Steininger et 
al., 2011). However, loss of Id3 has also been shown to be oncogenic. Id3 knockout mice 
can develop a γδ T cell lymphoma (Li et al., 2010). In human, a significant proportion of 
Burkitt’s lymphoma cases carry bi-allelic mutation of Id3, and restoring Id3 expression 
in the cancer cells resulted in cell death (Schmitz et al., 2012). These results imply that 
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E2A can also be an oncogene in certain situations, and Id3 becomes a tumor suppressor 
gene by inhibiting E2A. These conflicting results again highlight that the activity of E 
proteins and Id proteins need to be tightly and differentially regulated among different 
cell types, and an imbalance can easily result in either loss of the cell population or 
uncontrolled neoplasm. 
E2A has also been shown to be involved in several chromosome translocation 
and gene fusion events in different types of lymphoma/leukemia, such as the E2A-PBX1 
and the E2A-HLF fusions seen in 1 to 5% of childhood B cell precursor acute 
lymphoblastic leukemia (Aspland et al., 2001; LeBrun, 2003). The fusions result in the 
combination of the trans-activating domain of E2A and the DNA binding domain of the 
partner gene. These cancer cells often have deletion of the other non-translocated E2A 
allele. This results in loss of E2A regulation on its own target but enhanced or repressed 
transcription of the targets of the fusion partner. For example, E2A-PBX1 fusion can 
increase the expression of Wnt16, a component of the Wnt signaling pathway, while 
E2A-HLF can increase the expression of ABCB1, a membrane transporter that can render 
the cancer cells resistant to chemotherapies (LeBrun, 2003). 
 
1.4 New Materials and Methods Enable Investigation of E and Id 
Function in Previously Overlooked Compartments 
Although so much is known about the role of E and Id proteins, their function in 
several aspects of the immune system has never been probed in the past because of the 
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limitation of previously available materials and methods. For example, whether Id2 
plays a role in peripheral CD4 T cell responses was not known because Id2 knockout 
mice simply have no lymph node development (Yokota et al., 1999), which is important 
for CD4 T cell response to occur. The role of Id proteins in the development of γδ T cell 
development after they commit to the γδ lineage was not well studied, either; while Id3 
single knockout mice have a tremendous expansion of Vγ1.1+ Vδ6.3+ cells, indicating an 
inhibitory role of Id3 in the development of this subset of γδ T cells, whether Id2 plays a 
synergistic or compensatory role in their development is not known, since Id2 and Id3 
double knockout mice are not viable. And attempts to model human Burkitt’s 
lymphoma through c-Myc over-expression and Id3 knockout in mice was complicated 
by these mice’s preferential development of T cell, not B cell, lymphoma, as will be 
demonstrated in Chapter 4. We need to turn to newer conditional, tissue-specific 
knockout models of Id2 and Id3, as well as reporter strains, to address these questions. 
 In this thesis, I will discuss my work considering the following questions: first, 
does Id2 collaborate with Id3 in the control of γδ T cell development? Second, does Id2 
influence peripheral CD4 T cell responses?  Third, does Id3 collaborate with c-Myc in the 
formation of Burkitt’s’s lymphoma? These questions are explored in detail in the 
following three chapters. 
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2. Id2 is an inhibitor of the development of γδ T cells  
Part of the information in this chapter is originally published in The Journal of 
Immunology. Baojun Zhang, Yen-Yu Lin, Meifang Dai, and Yuan Zhuang. 2014. Id3 and 
Id2 act as a dual safety mechanism in regulating the development and population size of 
innate-like γδ T cells. J. Immunol. Vol 192(3):1055-63. Copyright © 2014 The American 
Association of Immunologists, Inc. 
(http://www.jimmunol.org/content/192/3/1055.abstract) 
2.1 Introduction 
γδ T cells are a subset of T lymphocytes generated in the thymus that function 
between the innate and adaptive immune system. They have features of the adaptive 
immune system, such as the expression of variable rearranged γδ T cell receptors, but 
they also have features of the innate immune system, such as the ability to respond to 
stimulation rapidly (Bonneville et al., 2010). They can directly lyse infected or stressed 
cells as well as interact with αβ T cells, B cells and dendritic cells and regulate their 
functions (Vantourout and Hayday, 2013). As a result, γδ T cells are involved in a broad 
range of immune processes, such as infection, inflammation, autoimmunity, tumor 
surveillance and tissue maintenance (Bonneville et al., 2010; Carding and Egan, 2002). 
These cells are produced in large numbers in the fetal and neonatal stages in mammals, 
disseminating and forming stable populations in internal organs, mucosal and body 
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surfaces, but their thymic production is gradually replaced by αβ T cells when the 
animal matures (Xiong and Raulet, 2007). The mechanism that controls the 
developmental switch from γδ to αβ T cell production in the thymus is not fully 
understood. 
Among γδ T cells, the cells that express the Vγ1.1 and Vδ6.3 segments of the γδ T 
cell receptor belong to a unique subset. In mice, these cells are produced in large 
numbers in the neonatal thymus (Grigoriadou et al., 2003) and are capable of rapidly 
producing multiple cytokines, including IFNγ and IL-4, upon stimulation (Azuara et al., 
2001). They express the transcription factor PLZF that is also found in NKT cells (Alonzo 
et al., 2010). Like NKT cells, they also have a significant presence in the liver (Gerber et 
al., 1999). The semi-invariant nature of their T cell receptor and their response pattern 
lead to the classification of these cells as “innate-like γδ T cells.” Although their function 
is not clearly understood, several studies pointed out that these cells may play an 
important role in attenuating excessive inflammation during infection and autoimmune 
processes due to their unique ability among γδ T cells to produce Th2-like cytokines (as 
reviewed by (Carding and Egan, 2002)). The population size of Vγ1.1+Vδ6.3+ γδ T cells 
varies between mouse strains; they are particularly abundant in the DBA strain (in 
which usually a Vδ6.4 segment is expressed) but relatively rare in the B6 strain (Azuara 
et al., 2001). However, in the absence of the helix-loop-helix transcription regulator, Id3, 
 27 
it has been shown that Vγ1.1+Vδ6.3+ γδ T cells can also expand dramatically in mice with 
B6 genetic background (Ueda-Hayakawa et al., 2009). 
As mentioned in Chapter 1, Id3 has been implicated to play both positive and 
negative roles in the developmental control of γδ T cells. It has been shown that in 
developing DN thymocytes, if a cell successfully rearranges the γδ T cell receptor genes, 
the surface expression of γδ T cell receptor can send a strong signal into the cell and up-
regulate Id3, promoting the cell to adopt a γδ T cell fate (Lauritsen et al., 2009). However, 
Id3 must also play a distinct inhibitory role controlling the development of Vγ1.1+Vδ6.3+ 
γδ T cells because this population is dramatically expanded in Id3 deficient mice. More 
interestingly, this expansion is limited to the neonatal window and cannot be 
recapitulated by transferring Id3-deficient bone marrow cells into adult wild type B6 
animals (Verykokakis et al., 2010). The expansion also requires a pure B6 genetic 
background; in a B6/129 mix background, the expansion is variable and often greatly 
diminished (Ueda-Hayakawa et al., 2009). The latter phenomenon suggests that 
additional gene(s) specific to the B6 background is also critical in the development of 
Vγ1.1+Vδ6.3+ γδ T cells in the absence of Id3. 
This strain- and genotype-specific expansion of Vγ1.1+Vδ6.3+ γδ T cells 
represents a unique opportunity to identify novel players in the developmental control 
of γδ T cells. In our lab, Baojun Zhang designed a backcross experiment between B6 and 
129 Id3-deficient mice with a goal to identify the background genes in regulating the 
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Vγ1.1+Vδ6.3+ γδ T cells. He found that another member of the Id protein family, Id2, was 
the major modifier of Id3 involved in the control of γδ T cell population size (Zhang et 
al., 2013). In B6/129 hybrid Id3-deficient mice, B6/B6 homozygosity in a locus on 
chromosome 12 close to the Id2 gene is strongly correlated with the expansion of these 
γδ T cells. Although there is no protein coding sequence difference, the Id2 129 allele is 
expressed more in γδ T cells than the Id2 B6 allele, suggesting that in the 129 strain, 
higher Id2 expression is inhibiting the development of Vγ1.1+Vδ6.3+ γδ T cells. In fact, 
bringing an Id2f allele, which was created on the 129 genetic background, into the Id3 
knockout mice can efficiently suppress the accumulation of Vγ1.1+Vδ6.3+ γδ T cells. 
However, when both Id2 and Id3 are completely deleted, the Vγ1.1+Vδ6.3+ γδ T cells do 
not expand more in the mouse than Id3 single knockout; on the contrary, the cells 
actually fail to accumulate, possibly due to attenuated proliferation and increased cell 
death induced by exceedingly high E protein activity (Zhang et al., 2013).  
In order to independently clarify the possible inhibitory role of Id2 in γδ T cell 
development, I studied the Id2GFP reporter mouse and the Id2f/fCD4Cre+ single 
conditional knockout mouse, and I found that Id2 is indeed expressed in the mature γδ 
T cells in the thymus, as well as in the Vγ1.1+Vδ6.3+ γδ T cells. Deletion of Id2 alone was 
sufficient to induce a moderate expansion of these populations, mainly through 
enhancing their survival. This results in an increase of γδ T cell numbers in the 
periphery. The results conclusively show that Id2 indeed is an inhibitor of γδ T cell 
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development, and support the idea that Id2 and Id3 act as dual safety mechanisms in 
regulating the population size of innate-like γδ T cells.  
 
2.2 Materials and Methods 
Mice 
 
The Id2GFP (Rawlins et al., 2009) and Id2f/f (Niola et al., 2012) mice have been 
described previously and both backcrossed to B6 background for more than 10 
generations. RosaZsGeen/ZsGreen mice on B6 background were purchased from Jackson 
Laboratories. CD4Cre transgenic mice on B6 background were purchased from Taconic. 
Animals were bred and maintained in the SPF facility managed by Duke University 
Division of Laboratory Animal Research.  All animal procedures were approved by the 
Duke University Institutional Animal Care and Use Committee.   
 
Flow cytometry 
 
The antibodies used in the flow cytometry analyses were as follows:  anti-mouse 
CD4 (GK1.5), anti-mouse CD8a (53-6.7), anti-mouse B220 (RA2-6B2), anti-mouse/human 
CD44 (IM7), anti-mouse CD25 (3C7), anti-mouse NK-1.1(PK136),  anti-mouse Ly-6G/Ly-
6C(Gr-1) (RB6-8C5),  anti-mouse CD11b(M1/70),  anti-mouse TCRγ/δ(GL3), anti-mouse 
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TCR Vγ1.1 (2.11), anti-mouse CD24 (M1/69), anti-mouse TCRβ (H57-597), anti-mouse 
IFNγ (XMG1.2) and anti-mouse IL-17A (TC11-18H10.1) were purchased from Biolegend.  
The PE anti-mouse Vδ 6.3/2 (8F4H7B7) antibody, annexin V and the APC BrdU Flow Kit 
were purchased from BD Biosciences. 7-Aminoactinomycin D (7-AAD) was purchased 
from Life Technologies. 
 
Single-cell suspensions were prepared from thymus, spleen and peripheral 
lymph nodes, and suspended in cold FACS buffer (1×PBS supplemented with 5% bovine 
calf serum).  1×106 cells were stained with antibodies in the dark at 4°C for 30 min.  After 
washing with cold FACS buffer, cell suspensions were analyzed on a FACSCanto II flow 
cytometer (BD Biosciences).  For intracellular staining, cells were stimulated with PMA 
(10 ng/mL) and ionomycin (1 μg/mL) in the presence of monensin (3μM) (all from 
Sigma-Aldrich) for 5 hours at 37℃, stained for surface markers and 7AAD, then fixed 
and permeabilized with the Cytofix/Cytoperm kit (BD), immediately followed by 
intracellular staining and flow cytometry analysis. FlowJo software (Tree Star) was used 
for data analysis.  Cell sorting was performed with a FACS DiVa sorter (BD Biosciences).  
 
In vitro stimulation of γδ T cells 
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Thymic GFP-negative TCRγδ+ cells from Id2GFP/+ mice were sorted and cultured 
in OP9-DL1 cell covered wells with MEM-α medium, supplemented with 10% fetal 
bovine serum and 5 ng/mL IL-7, with or without 1 μg/mL anti-TCRγδ (clone UC7-13D5, 
Biolegend). Cells were harvested after 5 days for FACS analysis. 
 
In vivo BrdU incorporation assays 
 
1 mg of BrdU was i.p. injected to each mouse 15 hours before sacrificing the 
mouse. Cells were harvested and processed with the BrdU Flow Kit (BD Biosciences) 
according to manufacturer protocol. 
 
Real-time PCR 
 
γδ T cells (TCRγδ+) were sorted from the mouse thymus, and their RNA was 
extracted with RNaqueous micro kit (Life Technologies). The RNA was reverse 
transcribed into cDNA with random hexamers and M-MLV reverse transcriptase (Life 
Technologies). Real-time PCR was performed with a Mastercycler ep realplex 
(Eppendorf). 18s rRNA was used as an internal control. The primer sequences are: 
PLZF-F, CCACCTTCGCTCACATACAG; PLZF-R, CACAGCCATTACACTCATAGGG; 
PLZF-probe, /56-FAM/TGCCGCAGA/ZEN/ACTCACACTCATATGG/3IABkFQ/; Itk-F, 
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GTGTTTGACTCCATCCCTCTC; Itk-R, CCCACTTCCCATATCTTAGCC; Itk-probe, /56-
FAM/CGACTCCGC/ZEN/TATCCAGTTTGCTCC/3IABkFQ; 18s rRNAF, GTT CCT TTG 
GTC GCT CGC TCC TC; 18S rRNAR, GGC ACG GCG ACT ACC ATC GA. 
 
Statistical analysis 
 
Sample data was compared using Student’s t test, and p value less than 0.05 was 
considered significant. 
2.3 Results 
2.3.1 Id2 is expressed in the mature γδ T cells 
To investigate the role of Id2 in the development of γδ T cells, I first examined its 
expression in γδ T cells using the Id2GFP reporter mouse. This mouse contains a GFP 
gene knock-in to the endogenous Id2 locus. The expression of GFP reflects the Id2 
promoter activity in individual cells. The knock-in allele does not express normal Id2 
mRNA, so Id2GFP/+ heterozygote mice were used to preserve Id2 function. The mouse 
was generated with 129 embryonic stem cells and later backcrossed to B6 background 
for more than 10 generations, but the expression level of Id2 should be similar to that 
observed in 129/sv mice. 
In the thymus, γδ T cells develop from DN3 cells that successfully rearrange the 
γδ T cell receptor. The nascent γδ T cells are TCRγδ+CD24+CD44low (“immature”); some 
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of these cells will go through a maturation process in the thymus and become 
TCRγδ+CD24-CD44hi (“mature”) (Prinz et al., 2006). Most γδ T cells in the periphery are 
CD24-, although they may have a variety of CD44 expression levels. 
Analyzing these populations from Id2GFP/+ mice, I found Id2 is not expressed in 
the precursors of γδ T cells (DN2, DN3) (Fig 3A). The expression is also not detectable in 
immature γδ T cells, but it is markedly increased in the mature γδ T cells. The γδ T cells 
that express T cell receptors using the Vγ1.1 and Vδ6.3 segments also expressed higher 
levels of Id2 compared to the γδ T cells that do not use both V segments (Fig 3B). 
It has been shown that γδ T cells maturing in the thymus may have encountered 
their cognate antigen and received signal through their TCRs (Haks et al., 2005). The 
Vγ1.1+Vδ6.3+ T cells have also been shown to be autoreactive (O'Brien et al., 1992). An 
increase of Id2 expression in the mature γδ T cells and in the Vγ1.1+Vδ6.3+ T cells 
suggests that Id2 may be up-regulated by TCR signaling. To test this hypothesis, I sorted 
GFP negative, TCRγδ+ cells from the thymi of Id2GFP/+ mice and cultured them with or 
without anti-TCRγδ antibody stimulation for 5 days. The TCR stimulation indeed 
resulted in higher Id2 expression (Fig 3C), supporting our hypothesis. 
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Figure 3: Id2 is expressed in thymic γδ T cells. 
(A) Examination of Id2 expression in developing γδ T cells in the thymus with an Id2GFP 
reporter showed that Id2 is up-regulated at the mature stage. DN2: Lin-CD25+CD44+. 
DN3: Lin-CD25+CD44-. Immature: TCRγδ+CD24+CD44low. Mature: TCRγδ+CD24-CD44high. 
(B) Id2 expression is higher in the Vγ1.1+Vδ6.3+ cells than in other γδ T cells. (C) In vitro 
culturing of sorted Id2GFP negative γδ T cells from the thymus for 5 days with IL-7 and 
anti-TCR γδ stimulation resulted in more significant up-regulation of Id2 compared to 
culturing with IL-7 alone. Data representative of 3 mice in each group. 
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2.3.2 Conditional Id2 deficiency results in increased numbers of γδ T 
cells in the periphery 
In order to understand the functional significance of the observed Id2 expression 
in developing γδ T cells, I utilized the Id2f/f CD4Cre conditional Id2 deficiency mouse 
model. CD4Cre is only active in a minor population of DN2 and DN3 cells, but it is 
highly active in the mature TCRγδ+ populations (Fig 4), making it a suitable deletor to 
study Id2 function in γδ T cells. 
In the spleen, the Id2f/f CD4Cre+ mice contained a larger population of γδ T cells 
than the Id2f/f CD4Cre- mice, both in terms of percentage and absolute numbers (Fig 5A-
B). This result clearly points out that Id2 is an inhibitor of γδ T cell development. The 
increase can be caused by an increase of thymic output or an increase of peripheral 
expansion. Although there appeared to be an increase in the percentage of γδ T cells in 
the thymus of Id2f/fCD4Cre+ mice, when the numbers of γδ T cells in the thymus were 
analyzed, no difference was observed between Id2f/fCD4Cre+ and Id2f/fCD4Cre- mice (Fig 
5C). The increase in γδ T cell percentage may reflect a decrease in numbers of other cell 
types, such as αβ T cells. This result indicates that Id2 deficiency does not directly 
increase numbers of thymic γδ T cells. However, Id2 may affect thymic γδ T cell output 
through other mechanisms. Previously, I found that mature γδ T cells in the thymus 
express higher levels of Id2. Mature γδ T cells from the thymus have been shown to 
have better survival in the periphery than immature γδ T cells (Tough and Sprent, 1998). 
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If deficiency of Id2 causes a change in the maturation of thymic γδ T cells, this can 
potentially contribute to a population size change of the peripheral γδ T cells. Therefore, 
I next performed more detailed analysis of thymic γδ T cells in the conditional knockout 
mice. 
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Figure 4: CD4Cre is active in the mature γδ T cells. 
Thymocytes from CD4Cre+ RosaZsGreen/+ mice were analyzed for ZsGreen expression. Cre 
activity will result in removal of a floxed transcription stop in the ZsGreen allele and 
induce permanent expression of ZsGreen, a green fluorescence marker. Although 
CD4Cre does not turn on ZsGreen in most DN2, DN3 and immature γδ T cells, it is 
highly active in mature γδ T cells. Data representative of 3 independent experiments. 
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Figure 5: Conditional Id2 deficient mice have more γδ T cells in the peripheral 
lymphoid organ. 
(A) Id2f/f CD4Cre+ mice have more γδ T cells in the spleen compared to Id2f/f CD4Cre- 
mice. (B) Statistical plots show the percentage and number of γδ T cells in the spleen of 
mice in each group. (C) Same analysis showed a higher percentage of γδ T cells in the 
Id2f/fCD4Cre+ mouse thymus but no increase in absolute numbers of the cells. Each dot 
represents one mouse. 
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2.3.3 Conditional Id2 deficiency increases the proportion of γδ T cells 
with a mature phenotype in the thymus 
As expected, in the Id2f/fCD4Cre+ mice, I found a larger population of CD24-
CD44hi mature γδ T cells in their thymi (Fig 6A). This increased maturation can be one of 
the possible explanations of the larger population of γδ T cells in the periphery. I also 
found that Id2f/fCD4Cre+ mice have a larger population of Vγ1.1+Vδ6.3+ T cells in their 
thymi, another population normally expressing high levels of Id2 (Fig 6B). Unlike the 
Id3 knockout mice, the expansion of Vγ1.1+Vδ6.3+ T cells in the Id2 conditional knockout 
mice is moderate and does not contribute to more than half of the total γδ T cells, 
suggesting that Id2 deficiency may lead to expansion of multiple subsets of γδ T cells, 
and the expansion is not limited to the Vγ1.1+Vδ6.3+ T cells only. 
In addition to the surface marker analysis, functional analysis also showed that 
γδ T cells from Id2f/fCD4Cre+ mice are more mature. There was an increase of IFNγ-
producing γδ T cells in their thymus, while the proportion of IL-17A-producing cells did 
not change (Fig 6C). Noticeably, the fluorescence intensity of intracellular staining of IL-
17A appeared to be variable among different mice, but there was no significant 
difference between Id2f/fCD4Cre+ mice and Id2f/fCD4Cre- mice (mean fluorescence 
intensity of IL-17A staining among the IL-17A positive cells: 84.3 ± 12.5 for Cre+ mice, 
78.13 ± 42 for Cre- mice, n=3 for each group) 
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It has been shown that γδ T cells which encounter their cognate antigens in the 
thymus will differentiate into IFNγ-producing cells, while those don’t encounter 
antigens differentiate into IL-17A-producing cells (Jensen et al., 2008). It is possible that 
in those cells which encounter their cognate antigen and receive TCR signaling in the 
thymus, Id2 is up-regulated and inhibits their development; therefore, when Id2 is 
removed, the population expands. 
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Figure 6: Conditional Id2 deficient mice have more mature γδ T cells and 
Vγ1.1+Vδ6.3+ T cells in the thymus. 
The proportion of CD24-CD44hi mature γδ T cells (A) and Vγ1.1+Vδ6.3+ T cells (B) is 
higher in the Id2f/fCD4Cre+ mouse thymus. (C) The percentage of IFNγ-producing 
population is also larger, but the IL-17A-producing population is not. Data 
representative of three independent experiments. 
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2.3.4 Conditional Id2 deficiency enhances the survival of γδ T cells in 
the thymus 
To investigate why Id2f/fCD4Cre+ mice have more mature γδ T cells in their 
thymus, I considered two possibilities. The cells may have improved survival or 
increased proliferation in the absence of Id2 inhibition. I stained the mature γδ T cells 
with 7AAD and annexin V and found that cells from Id2f/fCD4Cre+ mice contain fewer 
7AAD+ annexin V+ dead cells (Fig 7A). This indicates that the elevated level of Id2 
expression normally observed in these cells promotes their apoptosis; in the absence of 
Id2, the cells gain a survival advantage. On the other hand, when I analyzed the 
proliferation of mature γδ T cells using the BrdU incorporation assay, I did not observe a 
difference between Id2f/f CD4Cre+ and Id2f/f CD4Cre- mice (Fig 7B). This is in contrast to 
the previous report on the effect of Id3 deletion on Vγ1.1+Vδ6.3+ T cells, in which case 
the cells gain a tremendous proliferation capacity (Zhang et al., 2013). 
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Figure 7: Id2 deficient mature γδ T cells have improved survival but no 
proliferation advantage. 
(A) 7AAD/annexin V analysis showed that there is a smaller proportion of dead cells 
among mature γδ T cells in Id2f/fCD4Cre+ mice. (B) BrdU incorporation assay did not 
show a difference of proliferating cell percentage between Id2f/fCD4Cre+ mice and 
Id2f/fCD4Cre- mice. Each dot represents one mouse. 
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2.3.5 Id2 deficient mature γδ T cells express more PLZF and Itk 
To characterize the Id2-deficient γδ T cells further, I surveyed their mRNA 
expression of several factors important for γδ T cell maturation and function. I found 
that Id2-deficient γδ T cells express more PLZF, a transcription factor important for 
innate-like γδ T cells and NKT cells, as well as more Itk, a kinase mediating TCR 
signaling (Fig 8). This result may be caused by an expansion of the PLZFhi and/or Itkhi 
cell subset, or it can be caused by generally increased expression of the two genes on a 
per cell basis, or both. It has been shown that in NKT cells, PLZF is an important driver 
for the production of various cytokines such as IL-4, IFNγ and IL-17A (Alonzo and 
Sant'Angelo, 2011). Itk has been proposed to be a mediator of negative selection in γδ T 
cells; in the absence of Itk, potentially autoreactive γδ T cells can expand (Qi et al., 2011). 
The overall increase of PLZF and Itk expression among mature thymic γδ T cells in 
Id2f/fCD4Cre+ mice further suggests that this population may be not only larger in its size 
but also either contains more NKT-like and autoreactive cells, or be more NKT-like and 
autoreactive on a per cell basis, than those from wild type animals. 
 45 
 
Figure 8: mRNA expression of PLZF and Itk in thymic γδ T cells. 
Real-time PCR analysis of PLZF and Itk mRNA expression by thymic immature 
(CD24+CD44lo) and mature (CD24-CD44hi) TCRγδ+ cells. Each bar indicates the average of 
triplicates from one sample pooled from two mice. 
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2.4 Discussion 
The results of this study provide support for the genetic studies done by Baojun 
Zhang that Id2 indeed can function as an inhibitor of γδ T cell development. However, 
the phenotypic differences among wild type, Id3 knockout, Id2 single conditional 
knockout and Id2/Id3 double conditional knockout mice together create a complicated 
picture of E and Id function, defying a simple designation of these genes as pure 
inhibitors or enhancers of γδ T cell development. 
I propose a dual safety mechanism model to describe the role of Id2 and Id3 
specifically in the Vγ1.1+Vδ6.3+ γδ T cells (Fig 9). In this model, Id3 and Id2 are 
differentially regulated by the TCR signals. Egr is the major transcription factor acting 
between the TCR signal and Id3 in T cell development (Lauritsen et al., 2009).  PLZF is a 
unique transcription factor involved in the development of innate-like lymphocytes such 
as iNKT and Vγ1.1+Vδ6.3+ γδ T cells (Dutta et al., 2013; Kreslavsky et al., 2009). Id2 has 
been shown to be activated by PLZF, which is a direct target of Egr2 in iNKT cell 
development (Gleimer et al., 2012).  When both Id2 and Id3 are present, they respond to 
the TCR signal and keep E protein activity low, and consequently prevent the expansion 
of Vγ1.1+Vδ6.3+ γδ T cells. When Id3 is deleted, Id2 will assume a safety role to control E-
protein activity.  However, this safety role of Id2 is compromised by the hypomorphic 
allele of Id2 in the B6 background, allowing an increase in E protein activities to the  
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Figure 9: A schematic diagram of Vγ1.1+Vδ6.3+ γδ T cell developmental control 
by Id2 and Id3. 
In the developing thymus, γδ T cells that express the Vγ1.1 and Vδ6.3 TCR segments 
receive strong TCR signaling, up-regulating Id2 and Id3 through Egr1/2 and PLZF. The 
Id proteins inhibit activity of E proteins, affecting the survival and proliferation of 
Vγ1.1+Vδ6.3+ γδ T cells. When Id3 is present, and Id2 is expressed from a more active 
allele, such as the one from the 129 genetic background (Id2S, “strong”), E protein 
activity is very low and Vγ1.1+Vδ6.3+ γδ T cell population size is small. If Id3 is absent, 
and Id2 is expressed from a less active allele, such as the one from the B6 background 
(Id2B, “B6”), E protein activity becomes higher and the Vγ1.1+Vδ6.3+ γδ T cells expand 
dramatically. However, if both Id2 and Id3 are completely absent, E protein activity 
becomes too high and again impairs the survival and proliferation of Vγ1.1+Vδ6.3+ γδ T 
cells, limiting its population size. 
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optimal level for driving Vγ1.1+Vδ6.3+ γδ T cell expansion. When both Id2 and Id3 are 
completely deleted, E protein activity becomes too high and again limits the 
Vγ1.1+Vδ6.3+ γδ T cell population. 
Our study indicated that the level of E protein activity, regulated by Id2 and Id3 
expression levels, is crucial for γδ T cell development, especially during the 
“maturation” stage. Both very high and very low E protein activity can limit the 
accumulation of γδ T cells, especially the Vγ1.1+Vδ6.3+ γδ T cells. Since Id proteins are 
up-regulated by TCR signaling, a developmental restraint imposed by high Id protein 
level and low E activity can be interpreted as a mechanism the body uses to limit the 
number of γδ T cells that can recognize self antigen in the thymus, reiterating the idea 
that Id2 and Id3 are “dual safety” involved in the negative selection of γδ T cells 
(Lauritsen et al., 2009). However, this “negative selection” seems to be affected by the 
age of the animal and TCR V segment usage. The Vγ1.1+Vδ6.3+ γδ T cells, but not other 
autoreactive γδ T cells, dramatically expand during the neonatal period in Id3 deficient 
mice on B6 background. Why is this specific population particularly sensitive to Id 
protein regulation? One possibility is the presence of its cognate antigen. Vγ1.1+Vδ6.3+ 
γδ T cells have been shown to recognize HSP60 of both mouse and Mycobacteria origin 
(O'Brien et al., 1992). Expression level of this antigen or other possible ligands of the 
Vγ1.1+Vδ6.3+ γδ TCR may change in the thymus during development, thus making these 
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γδ T cells specifically prone to expand during the neonatal window, unless the Id 
proteins prevent them from doing so. Alternatively, the expression of Id proteins in 
response to TCR signaling may be different between cells generated in the neonatal 
period versus those generated in the adult stage, and different in cells utilizing other 
TCR V segments; mechanisms other than Id and E proteins may be more important in 
restraining autoreactive γδ T cells in those conditions, so they are less affected by Id 
protein deletion. Nevertheless, in the Id2 single conditional knockout mouse, γδ T cells 
other than those expressing Vγ1.1 and Vδ6.3 also expanded, indicating that Id2 is more 
broadly involved in the suppression of γδ T cell expansion. 
However, our study also showed that total loss of Id2 and Id3 can impair γδ T 
cell proliferation and survival. Unrestricted E protein activity can lead to death of T cells, 
especially effector and memory T cells, which is well documented in the studies of 
peripheral CD4 and CD8 αβ T cells (Cannarile et al., 2006; Lin et al., 2012b). γδ T cells 
are considered innate-like cells, and many of them have an effector phenotype even in 
the thymus (Bonneville et al., 2010). Therefore, it is not surprising that they share the 
same requirement of Id protein activity with effector αβ T cells.  
What is the physiological consequence of having a larger pool of autoreactive γδ 
T cells? The Id3 deficient mice spontaneously develop an autoimmune disease similar to 
human Sjogren’s syndrome (Li et al., 2004). The large population of Vγ1.1+Vδ6.3+ γδ T 
cells in these mice is potentially involved in the pathogenesis. However, a previous 
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report also showed that these cells can play a role in suppressing tissue inflammation 
(Carding and Egan, 2002). More tests are required to further clarify the impact of the 
expanded γδ T cell population in mice with Id protein deficiency. In the case of Id2, so 
far, I have not observed any signs of autoimmunity in the Id2 conditional knockout mice, 
despite their increased γδ T cell numbers. The impact of this enlarged population may 
become more prominent when the Id2 conditional knockout animal is challenged by 
triggers of autoimmune reactions that involve γδ T cells, such as imiquimod, which can 
induce a psoriasis-like skin disease (Cai et al., 2011). My hypothesis is the Id2 
conditional knockout mice may demonstrate a stronger γδ T cell response to the 
stimulation. 
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3. Id2 is required for the CD4 T cell immune response in 
the development of experimental autoimmune 
encephalomyelitis 
The information in this chapter is originally published in The Journal of 
Immunology. Yen-Yu Lin, Mary E. Jones-Mason, Makoto Inoue, Anna Lasorella, Antonio 
Iavarone, Qi-Jing Li, Mari L. Shinohara, Yuan Zhuang. 2012. Transcriptional regulator 
Id2 is required for the CD4 T cell immune response in the development of experimental 
autoimmune encephalomyelitis. J. Immunol. Vol 189(3):1400-5. Copyright © 2012 The 
American Association of Immunologists, Inc. 
(http://www.jimmunol.org/content/189/3/1400.long)  
3.1 Introduction 
The magnitude of a CD4 T cell response is a tightly controlled feature of the 
adaptive immune system. Upon activation through T cell receptor and co-stimulatory 
molecule signaling, a few antigen-specific CD4 T cells can proliferate to form a large 
pool of effector cells capable of performing immune functions. The expansion phase is 
then followed by contraction of the population to leave a small number of long-lived 
memory cells. Various intrinsic and extrinsic factors, including transcription factors and 
cytokines, have been implicated in regulating the T cell population size at each stage of 
this response (Taylor and Jenkins, 2011). For example, expression of the transcription 
factors T-bet (Joshi et al., 2007) and Blimp-1(Rutishauser et al., 2009) has been shown to 
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be associated with reduced T cell survival upon contraction, whereas IL-7 has been 
shown to promote T cell survival through this phase by promoting the expression of 
anti-apoptotic protein Bcl-2 (Kaech et al., 2003). However, why each individual T cell 
expresses different levels of these intrinsic factors, why each individual T cell responds 
differently to extrinsic factors and how these intrinsic-extrinsic factors cross-regulate 
each other are still not well understood. 
     As mentioned in Chapter 1, recently, the Inhibitor of DNA Binding (Id) 
proteins, including Id2 and Id3, have been identified to be important in the control of 
many aspects of T cell responses, including the T cell population size. In CD8 T cells, Id2 
and Id3 have been shown to control the numbers of effector and memory cells, at least 
partially through promoting T cell survival (Cannarile et al., 2006; Ji et al., 2011; Yang et 
al., 2011). However, relatively little is known about the role of Id2 in CD4 T cell 
responses. One previous report has shown that Id2-deficient mice have increased Th2 
dominance, but this difference was largely caused by the lack of a CD8+ dendritic cell 
subset and therefore was not necessarily related to Id2 function in CD4 T cells (Kusunoki 
et al., 2003). Nevertheless, two other studies with double-positive thymocytes (Jones and 
Zhuang, 2007) and pro-T cell lines (Schwartz et al., 2006) showed that E protein 
transcription factors, the direct target proteins of Id2, may regulate genes important for 
CD4 T cell responses, including apoptosis-related genes Bcl-2 and Bim, cell cycle-related 
genes Rb and Cdk6, and cytokine signal regulators SOCS1 and SOCS3(Jones and Zhuang, 
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2007; Schwartz et al., 2006). SOCS1 and SOCS3 directly control the CD4 T cell response 
to multiple cytokines regulating effector and/or memory function and population size, 
such as IL-7, IL-6, IL-12 and IL-15 (Chen et al., 2000). Many of those cytokines can also 
regulate the expression of Id2 (Yang et al., 2011). Thus, Id2 may be involved in the cross-
regulation of intrinsic and extrinsic factors for CD4 T cell population control. Thus far, 
studies based on Id2 knock-out mice cannot resolve these possibilities because the mice 
do not have normal development of lymph nodes (Yokota et al., 1999), and the model 
cannot separate CD4 T cell-intrinsic roles of Id2 from extrinsic ones. 
To investigate how Id2 is involved in CD4 T cell responses, we studied Id2 
conditional knock-out mice (Niola et al., 2012) with the experimental autoimmune 
encephalomyelitis (EAE) model, a CD4 T cell-dominant autoimmune disease model. 
EAE is a rodent model of human multiple sclerosis. By administering exogenous 
neuroautoantigens, a small number of pre-existing autoreactive CD4 T cells in the mice 
can be activated and induce central nervous system inflammation, demyelination and 
paralytic symptoms. The EAE model is an ideal tool to reveal potential roles of Id2 in 
many aspects of CD4 T cell responses, including T cell activation, differentiation, 
migration and population maintenance. With an Id2 reporter mouse model, we found 
that Id2 is dynamically regulated in the process of CD4 T cell activation. More strikingly, 
mice with T cell-specific Id2 deficiency are resistant to EAE, developing a smaller 
effector population in their peripheral lymphoid organs that fail to infiltrate the central 
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nervous system. This defect is at least in part due to reduced percentage of proliferating 
cells and increased death of effector CD4 T cells, and analysis of genes dysregulated in 
the absence of Id2 showed higher expression of Bim and SOCS3 in these cells. These 
results establish the importance of Id2 in effector CD4 T cell population size control.  
3.2 Materials and Methods 
Animals 
 
The Id2hCD5/hCD5 reporter mouse model has been reported previously (Jones-
Mason et al., 2012). Briefly, an IRES-driven, truncated human CD5 (hCD5) cDNA, 
without the sequence encoding the intracellular signaling domain, was knocked-in to 
the 3’ untranslated region of the Id2 gene. The Id2f/f mouse was used to generate 
conditional Id2 knock-out mice and has been described (Niola et al., 2012). The entire 
protein coding region of the Id2 gene was flanked by loxP sites. These mice were crossed 
with CD4-Cre transgenic mice (Taconic) to generate T cell-specific Id2-deficient mice 
(Δ/Δ, Id2f/f CD4Cre+). The CD4Cre transgene-negative littermates were used as wild type 
controls (f/f, Id2f/f CD4Cre-). All animal work was reviewed and approved by the Duke 
IACUC. 
 
T cell culture and stimulation 
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     Splenic CD44lowCD62L+ naïve CD4 T cells were sorted and cultured in 
RPMI1640 medium supplemented with 10% fetal bovine serum, 100 units/mL penicillin, 
100 μg/mL streptomycin and 55 μM 2-mercaptoethanol. For TCR stimulation, cells were 
treated with plate-bound anti-CD3ε (1 μg/mL) and anti-CD28 (2.5 μg/mL) (both from 
Biolegend) plus IL-2 (2 ng/mL, PeproTech). For un-stimulated wells, cells were treated 
with IL-2 only. 
 
Induction of EAE 
 
     EAE was induced in 6-week-old male mice by subcutaneous injection with 100 
μg myelin oligodendrocyte glycoprotein35-55 (MOG35-55) peptide 
(MEVGWYRSPFSRVVHLYRNGK, United Peptide Corporation) emulsified in 100μL 
CFA (Sigma-Aldrich) containing 2 mg/ml of heat-killed Mycobacterium tuberculosis 
H37RA (Difco). Mice were also injected intraperitoneally with 200ng of pertussis toxin 
(List Biological Laboratories) on day 0 and day 2. Clinical signs of EAE were recorded 
daily using a 0 to 4 scoring system: 0, normal; 1, limp tail; 2, unsteady gait; 3, hind-limb 
paralysis; 4, four-limb paralysis.  
 
Cell preparation and flow cytometry analysis 
 
 56 
     CD4 T cells were harvested from spleens and draining lymph nodes (inguinal 
and axillary). Mononuclear cells from the CNS were obtained as following: brain and 
spinal cord tissue were digested with 2.5 mg/mL collagenase D (Roche Applied Science) 
at 37℃ for 50 minutes. The tissue was then passed through a 70μm cell strainer and 
applied to Percoll gradient (30%/70%) centrifugation. Lymphocytes were collected from 
the interface. 
     Antibodies against CD4 (RM4-5), CD8α (53-6.7), CD44 (IM7), CD62L (MEL-14), 
IL-17A (Tc11-18H10.1), IFN-γ (XMG1.2) were from Biolegend. The antibody against 
human CD5 (hCD5, UCHT2) was from BD Bioscience. 7AAD was from Life 
Technologies. The mouse MOG38-49 I-A (b) tetramer was supplied by the NIH Tetramer 
Core Facility to identify the MOG-specific CD4 T cells. For surface staining, single-cell 
suspensions (2x106 cells) were stained for 15 minutes at 4℃. For tetramer staining, cells 
were stained for 3 hours at 37℃ as previously reported (Matsushita et al., 2008). For 
intracellular staining, cells were stimulated with PMA (10 ng/mL) and ionomycin (1 
μg/mL) in the presence of monensin (3μM) (all from Sigma-Aldrich) for 5 hours at 37℃, 
stained for surface markers and 7AAD, then fixed and permeabilized with the 
Cytofix/Cytoperm kit (BD), immediately followed by intracellular staining and flow 
cytometry analysis. For BrdU staining, 1 mg of BrdU in D-PBS was injected 
intraperitoneally 15 hours before sacrificing the animal, and the staining was performed 
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with the BD BrdU Flow Kit according to manufacturer protocols. Cells were analyzed 
with a FACSCanto flow cytometer (BD) or sorted with a MoFlo cell sorter (Beckman 
Coulter). 
 
Real-time PCR 
 
     Splenocytes were harvested from mice 9 days after EAE induction. CD4 T cells 
were enriched with the EasySep mouse CD4+ T cell enrichment kit (Stemcell 
Technologies). MOG I-A(b)+CD4+ T cells were sorted, and total RNA from the cells were 
extracted followed by DNase I treatment using the RNAqueous micro kit (Life 
Technologies). Reverse transcription was performed with M-MLV reverse transcriptase 
(Life Technologies). The cDNA was used for real-time PCR with a Mastercycler ep 
realplex (Eppendorf). 18s rRNA was used as an internal control. The primer sequences 
are: Bcl2F, GGACTTGAAGTGCCATTGGTA; Bcl2R, GTTATCATACCCTGTTCTCCCG; 
Bcl2probe, /56-FAM/TGCGCCATC/ZEN/CTTCCCCGAAA/3IABkFQ/; BimF, 
GAGATACGGATTGCACAGGAG; BimR, CGGAAGATAAAGCGTAACAGTTG; 
Bimprobe, /56-FAM/TTCAGCCTC/ZEN/GCGGTAATCATTTGC/3IABkFQ/; SOCS1F, 
CTGCAGGAGCTGTGTCG; SOCS1R, CCCCACTTAATGCTGCGG; SOCS1probe, /56-
FAM/CGCATCCCT/ZEN/CTTAACCCGGTACTC/3IABkFQ/; SOCS3F, 
CCTATGAGAAAGTGACCCAGC; SOCS3R, TTTGTGCTTGTGCCATGTG; SOCS3probe, 
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/56-FAM/CCCCTCTGA/ZEN/CCCTTTTGCTCCTT/3IABkFQ/; 18s rRNAF, GTT CCT 
TTG GTC GCT CGC TCC TC; 18S rRNAR, GGC ACG GCG ACT ACC ATC GA. 
3.3 Results 
3.3.1 Activated CD4 T cells express higher levels of Id2 than naive 
CD4 T cells 
We used an Id2hCD5/hCD5 reporter mouse model, in which surface hCD5 expression 
can be used as a marker for cellular Id2 expression (Jones-Mason et al., 2012), to first 
investigate the expression of Id2 in different subsets of CD4 T cells. In the spleen of 
naïve mice, we found that CD44hiCD62L- effector memory-like CD4 T cells expressed 
higher levels of hCD5 than the CD44hiCD62L+ central memory-like or the CD44lowCD62L+ 
naïve CD4 T cells (Fig 10A), suggesting that Id2 expression is correlated with previous T 
cell activation. Because the exact activation history of the pre-existing effector memory-
like CD4 T cells is not defined in these mice, we next sorted CD44lowCD62L+ naïve CD4 T 
cells and cultured them with anti-CD3/anti-CD28 stimulation plus IL-2 or with IL-2 only. 
After 48 hours of culture, the TCR-stimulated cells expressed higher levels of hCD5 than 
the un-stimulated cells (Fig 10B), showing that Id2 is dynamically regulated in the 
process of T cell activation. In order to confirm this finding in vivo, we induced EAE, a 
CD4 T cell-mediated autoimmune disease, in the Id2hCD5/hCD5 reporter mice. Nine days 
after subcutaneous immunization with MOG peptide, we analyzed the MOG-specific 
CD4 T cells, as well as IL-17A and/or IFNγ-producing CD4 T cells from the draining 
lymph nodes. We again found that these cells expressed higher levels of hCD5 than the 
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non-MOG-specific or non-cytokine-producing CD4 T cells (Fig 10C-D). The in vitro and 
in vivo findings of Id2 up-regulation after CD4 T cell activation suggest that Id2 may 
play a role during the activation process and/or in the maintenance of the activated T 
cells. 
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Figure 10: Activated CD4 T cells express higher levels of Id2 than naïve CD4 T 
cells 
(A) The expression of hCD5 by subsets of splenic CD4 T cells from Id2hCD5/hCD5 reporter 
mice was analyzed. Left: gating of the subsets. Right: histograms showing the hCD5 
expression of CD44hiCD62L- (orange), CD44hiCD62L+ (red) and CD44lowCD62L+ (blue) 
CD4 T cells. (B) Splenic CD44lowCD62L+ naïve CD4 T cells from Id2hCD5/hCD5 reporter mice 
were sorted and cultured with anti-CD3/anti-CD28 antibodies plus IL-2 (red) or with IL-
2 only (blue). Histograms show their hCD5 expression before, 24 hours and 48 hours 
after culture. (C) Expression of hCD5 by MOG I-A (b)+ (red) or MOG I-A (b)- (blue) CD4 
T cells isolated from draining lymph nodes of Id2hCD5/hCD5 reporter mice 9 days after EAE 
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induction. (D) Expression of hCD5 by IL-17A+IFNγ+ (blue), IL-17A-IFNγ+ (black), IL-
17A+IFNγ- (red) and IL-17A-IFNγ- (orange) CD4 T cells from the same lymph nodes as C. 
Numbers above histograms indicate mean fluorescence intensity. Shaded histograms in 
each plot showed hCD5 background of comparable populations of wild type CD4 T cells. 
All plots are representative of three independent experiments. 
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3.3.2 Mice with T cell-specific Id2 deficiency do not develop EAE 
To test the functional significance of the up-regulation of Id2 expression in CD4 T 
cells during immune responses in vivo, we utilized the EAE model to compare the 
control (f/f, Id2f/fCD4Cre-) mice versus T cell-specific Id2-deficient (Δ/Δ, Id2f/f CD4Cre+) 
mice. Both mice have grossly normal inguinal (Fig 11A) and axillary (data not shown) 
lymph node development. In the naïve mice, despite a small reduction in total 
thymocyte numbers, the T cell-specific Id2-deficient mice have similar thymocyte 
development and splenic CD4 T cell composition compared to the control mice (Fig 12A 
to H). Similarly, no difference was observed with inguinal and axillary lymph node cell 
analysis (data not shown). The Id2-deficient CD4 T cells are also able to differentiate into 
IL-17-producing Th17 cells in vitro, with ability to survive and proliferate comparable to 
the control cells (Fig 12I). After immunization with MOG peptide, all control mice 
developed paralytic symptoms characteristic of EAE; however, none of the T cell-specific 
Id2-deficient mice developed the disease (Fig 11B). Because the development of disease 
symptoms in the EAE model is critically dependent on CD4 T cell infiltration into the 
CNS, we analyzed the CNS tissue from the mice 15 days after EAE induction, when the 
disease severity was at its peak in control mice. While we found a significant number of 
CD4 T cells in the brain and spinal cord of control mice, nearly no CD4 T cell infiltration 
was observed in the CNS of T cell-specific Id2-deficient mice (Fig 13A-B). The CD4 T 
cells found in the CNS of control mice consist of a significant proportion of MOG-
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specific cells, as well as IL-17 and/or IFNγ producing cells, while the few CD4 T cells 
found in the CNS of T cell-specific Id2-deficient mice do not contain these populations 
(Fig 13C-D). Together, the complete resistance to the disease and the absence of T cell 
infiltration in the CNS showed that Id2 expression is indeed functionally relevant to 
CD4 T cell responses in vivo, and Id2 deficiency may cause a significant defect in CD4 T 
cell response to MOG immunization, possibly early in the initiation phase of the disease. 
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Figure 11: Mice with T cell-specific Id2 deficiency are resistant to EAE 
(A) Representative photographs of inguinal lymph nodes (circled by dashed lines) from 
control (f/f, Id2f/fCD4Cre-) and T cell-specific Id2-deficient (Δ/Δ, Id2f/fCD4Cre+) mice. n=5 
for each group. (B) EAE was induced in six-week-old mice, and their disease scores were 
recorded daily. Score 0: normal, 1: limp tail, 2: unsteady gait, 3: hind limb paralysis, 4: 
four limb paralysis. f/f, n=6; Δ/Δ, n=7. Error bars indicate S.D. 
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Figure 12: Mice with T cell-specific Id2 deficiency have similar thymocyte 
development, splenic CD4 T cell composition and in vitro Th17 differentiation 
compared to control mice 
(A) Representative thymocyte flow cytometry analysis shows percentage of double 
positive and single positive thymocytes in control (f/f) and T cell-specific Id2-deficient 
mice (Δ/Δ). Bar graphs compare (B) total thymocyte numbers, (C) percentage of double 
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positive cells and (D) percentage of CD4 single positive (CD4SP) and CD8 single 
positive (CD8SP) cells between the two groups. (E) Representative splenocyte flow 
cytometry analysis shows percentage of CD4+ and CD8+ T cells. (F) Numbers of total 
splenic CD4+ cells. (G and H) Representative flow cytometry analysis and bar graph 
show the percentage of subsets of splenic CD4+ T cells. (I) Analysis of CD4+ T cells 8 days 
after in vitro culture in Th17 skewing condition. Splenic CD4+ cells from naïve control 
and T cell-specific Id2-deficient mice were magnetically enriched and cultured in the 
presence of anti-CD3 (5 μg/mL), anti-CD28 (1 μg/mL), TGF-β (1 ng/mL), IL-6 (50 ng/mL), 
IL-23 (50 ng/mL), IL-1β (20 ng/mL), anti-IFNγ (10 μg/mL) and anti-IL-4 (10μg/mL). n=3 
for each group in each graph. *p < 0.05. Error bars indicate S.D. 
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Figure 13: Mice with T cell-specific Id2 deficiency do not recruit CD4 T cells 
into the CNS 15 days after EAE induction 
(A) Representative plots of CD4 and CD8α staining of CNS infiltrating cells. (B) 
Percentage and number of CD4 T cells in the CNS. n=3 for each group.  *p<0.05. Error 
bars indicate S.D. (C) Representative plots of MOG I-A(b) staining of CNS infiltrating 
CD4+ cells. (D) Representative plots of IL-17A and IFNγ staining of CNS infiltrating 
CD4+ cells.  
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3.3.3 EAE induction generates a smaller pool of effector CD4 T cells 
in mice with T cell-specific Id2 deficiency 
Two possibilities may lead to the absence of CD4 T cell infiltration to the CNS in 
mice with Id2 deficiency: the effector CD4 T cells may develop in the periphery 
normally, but fail to migrate to the CNS, or the development of the effector T cells may 
be defective. To distinguish these possibilities, we next examined the CD4 T cell 
response in peripheral lymphoid organs of the mice 9 days after immunization, when 
control mice started to show paralytic symptoms. Compared to control mice, the 
percentage and number of MOG-specific CD4 T cells was lower in the T cell-specific Id2-
deficient mice both in the spleen and draining lymph nodes (Fig 14A). Intracellular 
cytokine staining also revealed a decrease of splenic cytokine-producing CD4 T cell 
populations in the T cell-specific Id2-deficient mice (Fig 14B), especially the IL-17A+IFN-
γ+ cells, which have been reported to be especially encephalitogenic (Kebir et al., 2009). 
These results correlate with the higher expression of Id2 seen in these populations in the 
Id2hCD5/hCD5 model (Fig 10C-D). It is noteworthy that residual MOG-specific and 
cytokine-producing CD4 T cells can be detected in the T cell-specific Id2-deficient mice, 
suggesting that these T cells have not totally lost their capability of activation and 
differentiation; presence of these cells in the spleen but not in the CNS also suggests that 
they have entered circulation but possibly failed to enter CNS. Several adhesion 
molecules and chemokine receptors have been shown to be important for the migration 
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of T cells in EAE, including α4β1 integrin (Rice et al., 2005) and CCR6 (Reboldi et al., 
2009). We examined the expression levels of the two molecules by MOG-specific T cells 
from mice 9 days after EAE induction but found no difference between Id2-deficient and 
control cells (Fig 15). Therefore, the absence of Id2-deficient CD4 T cells in CNS is 
unlikely caused by change in the expression of α4β1 integrin or CCR6. 
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Figure 14: Mice with T cell-specific Id2 deficiency have a smaller pool of 
effector CD4 T cells in the secondary lymphoid organs 9 days after EAE induction 
(A) Representative plots and bar graphs showing percentages and numbers of MOG-
specific cells among CD4 T cells from spleens of control (f/f) and Id2 conditional knock-
out (Δ/Δ) mice. Similar changes were observed in the lymph nodes as shown in the bar 
graphs. (B) Representative plots and bar graphs of cytokine-producing CD4 T cells from 
spleens of control (f/f) and Id2 conditional knock-out (Δ/Δ) mice. n≥3 for each group. *p 
< 0.05. Error bars indicate S.D. 
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Figure 15: Id2-deficient MOG-specific CD4 T cells have similar expressions of 
α4β1 integrin and CCR6 compared to control cells 
(A) Representative splenocyte plots and bar graphs showing the expression of α4β1 
integrin by MOG-specific cells from spleens and lymph nodes from mice 9 days after 
EAE induction. (B) Representative splenocyte plots and bar graphs showing the 
expression of CCR6 by the same MOG-specific cell populations. Shaded histogram 
showed CCR6 staining of total CD4 T cells. n=3 for each group. Error bars indicate S.D. 
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3.3.4 Id2-deficient CD4 T cells show reduced percentage of 
proliferating cells and increased cell death 
A smaller population of effector T cells may be the result of reduced cell 
proliferation or increased cell death. We examined the proliferation of MOG-specific 
CD4 T cells in the expansion phase of the immune response (6 days after EAE induction) 
by in vivo BrdU labeling. We found a significant decrease of percentage of BrdU+ cells 
from the draining lymph nodes of T cell-specific Id2-deficient mice compared to the 
control mice (Fig 16A).We next compared cell death between control and Id2-deficient 
CD4 T cells with 7AAD staining. Corresponding to their reduced population size, we 
found increased cell death in MOG-specific CD4 T cells as well as IL-17A+IFN-γ+ CD4 T 
cells from T cell-specific Id2-deficient mice 9 days after EAE induction (Fig 16B-C). 
Repeating the experiments with a fixable Live/Dead stain (Life Technologies) generated 
similar results (data not shown). These findings indicate that Id2-deficient CD4 T cells, 
after activation, suffer from reduced proliferation, increased cell death, form a smaller 
effector cell population, and are unable to induce EAE. 
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Figure 16: Id2-deficient CD4 T cells show reduced percentage of proliferating 
cells and undergo increased cell death 
(A) Proliferating cells were labeled in vivo with BrdU 6 days after EAE induction. Cells 
from draining lymph nodes were analyzed 15 hours after BrdU injection. Line histogram: 
MOG I-A (b)+ CD4+ cells; shaded histogram: MOG I-A (b)+ CD4+ cells from mice not 
injected with BrdU. (B and C) Cell death of the Id2-deficient MOG-specific CD4 T cell 
and IL-17A+IFNγ+ CD4 T cell populations 9 days after EAE induction were shown by 
7AAD staining. (B) Line histogram: splenic MOG I-A (b)+ cells; shaded histogram: MOG 
I-A (b)- cells. (C) Line histogram: splenic IL-17A+IFNγ+ CD4 T cells. Bar graph shown is 
analysis of splenic CD4 T cells. n≥3 for each group. *p < 0.05. Error bars indicate S.D. 
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3.3.5 Id2-deficient CD4 T cells express higher levels of Bim and 
SOCS3 
Two possible mechanisms may explain how Id2 affects the CD4 T cell population 
size: direct control of apoptosis or inhibition of cytokine signaling. Both anti-apoptotic 
and pro-apoptotic genes, such as Bcl-2 and Bim, have been reported to be altered in Id2-
deficient CD8 T cells (Cannarile et al., 2006). We used real-time PCR to examine their 
expressions in splenic MOG-specific CD4 T cells from animals 9 days after EAE 
induction, and we found that the expression of the pro-apoptotic Bim was increased in 
Id2-deficient CD4 T cells but not Bcl-2 (Fig 17A). This result correlates with the increased 
cell death of this population and is compatible with a previous report that E proteins can 
up-regulate Bim expression (Schwartz et al., 2006).  
In addition to direct regulation of apoptosis, Id2 may also regulate cell survival 
and other aspects of T cell responses through regulation of cytokine signaling. Two 
important suppressors of cytokine signaling in T cells, SOCS1 and SOCS3, have been 
reported to be up-regulated by E proteins (Jones and Zhuang, 2007; Schwartz et al., 
2006). In particular, increased SOCS3 can inhibit cytokine signaling through STAT3, an 
important signal transduction mediator of pro-inflammatory cytokines such as IL-6 
(Baker et al., 2009). T cell-specific STAT3 knock-out mice are also resistant to EAE and 
also demonstrate a reduced size of IL-17-producing effector CD4 T cell population (Liu 
et al., 2008). We examined the expression of Socs1 and Socs3 in Id2-deficient MOG-
specific CD4 T cells by real-time PCR and found that Socs3 expression was profoundly 
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up-regulated compared to control CD4 T cells; there was also a trend toward increased 
Socs1 expression in these cells (Fig 17B). These results indicate that Id2 is required for 
the maintenance of the effector CD4 T cell population size through regulating the 
expression of genes related to apoptosis control and cytokine signaling. 
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Figure 17: Id2-deficient MOG-specific CD4 T cells express higher levels of Bim 
and Socs3 mRNA 
Real-time PCR analysis of Bcl-2, Bim (A), Socs1 and Socs3 (B) mRNA expression by sorted 
Id2-deficient MOG I-A (b)+ CD4 T cells from spleens of mice 9 days after EAE induction, 
normalized to their control counter parts. Each dot represents an individual animal. *p < 
0.05 
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3.4 Discussion 
Once CD4 T cells get activated in an immune response, both intrinsic and 
extrinsic factors contribute to the maintenance and regulation of the effector T cells, 
controlling the size of the population and the function of individual cells. Here we 
demonstrate that transcriptional regulator Id2, previously best known for its role in the 
development of various lineages of hematopoietic cells (Kee, 2009), is also an important 
regulator of CD4 T cell responses, especially in the Th17-mediated EAE disease model. 
In the absence of Id2, the population size of MOG-specific CD4 T cells is reduced. 
The cytokine-producing CD4 T cells are also reduced; specifically, we found that IL-
17A+IFNγ+ CD4 T cells almost completely disappeared in the T cell-specific Id2-deficient 
mice. The findings implied that this population is particularly dependent on Id2 for its 
formation and/or survival. Previous studies reported that this population is more 
encephalitogenic and has a stronger propensity to migrate into the central nervous 
system (Kebir et al., 2009). In a tumor model, the IFNγ production capacity of Th17 cells 
has also been shown to be crucial for their anti-tumor activity (Muranski et al., 2011). 
These reports suggest that the IL-17A+IFNγ+ CD4 T cells may be important effector cells 
of a Th17-mediated immune response. They also help explain that, despite relatively 
comparable development of IL-17A+ or IFNγ+ CD4 T cells in the peripheral lymphoid 
organs of the T cell-specific Id2-deficient mice, and a reduced but still significant 
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population of MOG-specific CD4 T cell, no CNS infiltration or disease symptoms 
developed in these mice. Why this population is particularly dependent on Id2, and 
whether the population can be specifically targeted for controlling Th17-mediated 
autoimmune diseases, remain important questions to be addressed.  
One possible explanation lies in Id2-mediated regulation of SOCS3. By removing 
the inhibitor Id2, SOCS3 expression increases. SOCS3 can suppress signaling of many 
Th17-related cytokines, including IL-21 and IL-23, through its association with the 
cytokine receptor and inhibition of JAK kinases, reducing the phosphorylation and 
activation of the downstream signal transduction molecule STAT3 (Baker et al., 2009). 
IL-21 production is up-regulated in Th17 cells upon IL-6 stimulation, and it can up-
regulate the expression of IL-23 receptor by Th17 cells, increasing the cellular 
responsiveness to IL-23 and thus “stabilize” Th17 cells (Spolski and Leonard, 2008). IL-
23 signaling is critical for the development of IL-17+IFNγ+ as well as IL-17-IFNγ+ cells 
from IL-17+ cells during chronic inflammation, such as in EAE (Hirota et al., 2011). In the 
absence of Id2, these cytokine signaling processes may be impaired by SOCS3, thus 
impairing Th17 maintenance and evolution. In fact, T cell-specific STAT3 deficient mice 
are also resistant to EAE and experimental autoimmune uveitis (EAU) (Liu et al., 2008). 
These mice also have significantly reduced IL-17A+IFNγ+ CD4 T cells in the periphery. 
The phenotype similarity between STAT3-deficient CD4 T cells and Id2-deficeint CD4 T 
cells, and the up-regulation of SOCS3 in the latter, strongly suggests that Id2 influence 
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CD4 T cells through their regulation of cellular responses to cytokines. However, 
because E proteins and Id proteins regulate many genes, it is possible that other 
important pathways are also affected in the Id2-deficient CD4 T cells. A gene expression 
profiling experiment should provide us with a comprehensive overview of these 
potentially Id2-regulated pathways. 
The current study focuses on the role of Id2 in the effector stage of the CD4 T cell 
immune response. Whether Id2 plays a role in the formation of CD4 T cell memory is 
also an important question. Yang et al previously showed that Id2 is important for the 
formation of short-lived effector memory CD8 T cells in a Listeria infection model (Yang 
et al., 2011). The possibility that Id2 contributes to the survival of effector memory CD4 
T cells can be tested in the future with a variety of prime-boost immunization models or 
infection-rechallenge models. In addition, as shown in Chapter 2, Id2 also plays a 
significant role in the development of γδ T cells, and CD4Cre is capable of deleting Id2 
in γδ T cells. It is likely that the disturbance of Id2 function in γδ T cells also influenced 
the disease resistance demonstrated by the Id2 conditional knockout mice in this chapter. 
Whether γδ T cells get activated in the periphery of these mice, how well is their 
population maintained, and whether Id2-deficient γδ T cells can invade the CNS, 
require further studies to clarify. 
We have shown in this study that mice with T cell-specific Id2 deficiency do not 
develop EAE. However, whether removing Id2 after the disease already develops, such 
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as using chemical inhibitors of Id2 or inducible Id2 deletion models, can alter the disease 
course, is another interesting question. We predict that removal of Id2 after T cell 
activation should also be effective in inhibiting the T cell response, possibly by shrinking 
the effector T cell population through increased cell death. If confirmed, modulation of E 
protein-Id protein activity may become a possible direction of the development of future 
immune suppressive treatments. 
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4. Id3 inhibits tumor genesis driven by the EµMyc 
transgene in the lymphoid system 
4.1 Introduction 
Burkitt’s lymphoma is a kind of homogeneous, medium sized B cell lymphoma 
that is the most rapidly progressive human tumor across all organ systems (Longo, 2011). 
The tumor size can double every 24 to 48 hours because almost 100% of the tumor cells 
are proliferative. The disease can also present in the form of leukemia. It has such an 
aggressive behavior probably because it originates from germinal center B cells, which 
naturally proliferate quickly and undergo somatic hypermutations for the selection and 
expansion of high affinity antibody-producing cells. 
There are three different kinds of Burkitt’s lymphoma: endemic, sporadic and 
immunodeficiency-associated. The endemic form is mostly found in Africa and is 
associated with Ebstein-Barr Virus infection. The immunodeficiency-associated form is 
commonly seen in patients infected with HIV. The sporadic form has no identifiable 
cause, and it typically occurs in children or young adults, presenting as peripheral 
lymphadenopathy or an intraabdominal mass. The sporadic form is a rare disease in 
Western countries, with an incidence of 3 per 1,000,000 people per year (Longo, 2011). 
Regardless of the kind, all Burkitt’s lymphoma can be rapidly lethal if not treated 
quickly. Although modern combination chemotherapy can cure up to 70-80% of patients 
with Burkitt’s lymphoma, the chemotherapy agents used are highly toxic, and a small 
proportion of patients still have resistant diseases or relapses (Molyneux et al., 2012). 
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Therefore, further investigation of the disease is needed to design new treatments and to 
improve care of these patients.  
The sporadic form of Burkitt’s lymphoma has long been associated with the 
t(8;14) chromosome translocation event, which brings the proto-oncogene c-Myc 
together with immunoglobulin heavy chain (IgH) gene and leads to over-expression of 
c-Myc in B cells. This is thought to contribute to the hyper-proliferative capacity of the 
tumor cells. Myc is a basic helix-loop-helix zipper (bHLH-Zip) protein and binds to 
DNA with its partner MAX (another bHLH-Zip protein), and together they recognize 
target sequences containing E box consensus sequences (CACGTG), similar to those 
recognized by E proteins (Blackwood and Eisenman, 1991). Because E box consensus 
sequences are present in a large number of genes, Myc has been proposed to be a global 
regulator of chromatin and gene expression, and cells that express more Myc have 
higher transcription activity in general and contain more RNA per cell (Loven et al., 
2012). This results in more cell cycle progression and metabolism through glycolysis 
(Ward and Thompson, 2012). However, in vitro over-expression of c-Myc also leads to 
rapid cell death (Wang et al., 2011); Burkitt’s lymphoma cells must have other genetic 
changes to avoid this consequence. Several reported genetic changes that may serve this 
function include mutations in p53, Bim, cyclin D3/CDK6, and PI(3) Kinase (Egle et al., 
2004; Love et al., 2012). However, none of these is as common as the c-Myc translocation 
event. 
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 Over-expressing c-Myc alone in mice through introduction of a IgH-c-Myc 
fusion transgene (EμMyc) indeed can induce B cell lymphoma/leukemia, but the cancer 
cells do not demonstrate all the features of Burkitt’s lymphoma. In fact, many tumors 
thus derived are pro B or pre B cell lymphoma, and the mature B cell lymphomas do not 
show characteristics of germinal center B cells (Adams et al., 1985). Other mouse models, 
such as one that co-overexpress c-Myc and a constitutively active PI (3) kinase in 
germinal center B cells, demonstrate more similarity to human Burkitt’s lymphoma 
(Sander et al., 2012). Nevertheless, a best mouse model should incorporate mutations or 
other genetic changes that are commonly found in human tumors and demonstrate 
human tumor-like behavior, and this requires more knowledge about the genetic 
derangements in the human Burkitt’s lymphoma patients. 
Recently, the rapidly developing Next Generation Sequencing (NGS) technology 
made it possible for investigators to sequence entire genomes of cancer cells and normal 
cells from multiple patients. Application of this technology to Burkitt’s lymphoma led to 
identification of new common mutations occurring in multiple patients that might 
contribute to the transformation process of these cells. One of the most commonly 
mutated genes is the helix-loop-helix transcription regulator, Inhibitor of DNA Binding 
3 (Id3). In fact, up to 60% of Burkitt’s lymphoma samples carry Id3 mutation, mostly 
causing loss of Id3 expression or function (Schmitz et al., 2012). Interestingly, similar 
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studies conducted by our collaborator, Dr. Sandeep Dave’s group, showed that Id3 
mutation only exists in the tumors with c-Myc mutations and is rarely seen in other B 
cell malignancies such as diffuse large B cell lymphoma (Love et al., 2012). 
As discussed in Chapter 1, deficiency of E proteins and Id proteins has been 
shown to cause or associate with hematopoietic malignancies in different mouse models 
and human diseases. Therefore, it is highly likely that Id3 may play a role in the 
transformation process of Burkitt’s lymphoma. In fact, a recent publication pointed out 
that Id3 and E2A may regulate the activity of B cell receptor signaling, which is 
important for the survival of Burkitt’s lymphoma cells (Schmitz et al., 2012). Dr. Sandeep 
Dave’s group also showed that over-expressing mutant Id3 promoted Burkitt’s 
lymphoma cell proliferation (Love et al., 2012). However, the studies were performed 
with lymphoma cell lines. It is still unknown at which stage of the transformation 
process Id3 is mutated and what role it actually plays in vivo. 
Paradoxically, we have reported in the past that Id3-deficient B cells actually 
have impaired proliferation capacity, in contrast to their potential oncogenic role in 
Burkitt’s lymphoma (Pan et al., 1999). This may suggest a unique interaction between 
Id3 and c-Myc and correlate with the exclusive presence of Id3 mutation in Burkitt’s 
lymphoma. Following the exciting discovery made in Dr. Dave’s laboratory, we 
collaborated with Dr. Dave to investigate genetic interactions between Id3 and c-Myc. 
As a pilot project, we started the collaboration by establishing Id3-deficient, c-Myc over 
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expressing mice. We plan to utilize this model to study the role of Id3 in the 
development of Burkitt’s lymphoma-like disease in the mice. The study can help us 
understand why the mutation of this gene is so common in Burkitt’s lymphoma yet so 
rare in other kinds of B cell malignancies, and whether targeting Id3 and E proteins will 
be a potential therapeutic option for the treatment of Burkitt’s lymphoma.  
4.2 Materials and Methods 
Mice 
 
The Id3-/- (Pan et al., 1999) and Id3f/f (Guo et al., 2011) mice have been described 
previously and all maintained on pure B6 background. The EμMyc transgenic mice and 
AIDCre transgenic mice were purchased from The Jackson Laboratory. Animals were 
bred and maintained in the SPF facility managed by Duke University Division of 
Laboratory Animal Research.  All animal procedures were approved by the Duke 
University Institutional Animal Care and Use Committee.   
 
Germinal center induction 
 
To induce germinal center formation, 6 to 8 weeks old mice were immunized 
with a mixture of 4-Hydroxy-3-nitrophenylacetyl haptenated chicken gamma globulin 
(NP-CGG) (0.2 mg per mouse) (Biosearch Technologies) and aluminum sulfate (alum) 
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(100mg per mouse) (EMD Millipore) through i.p. injection. 10 days later, immunized 
mice were sacrificed, and their splenocytes were harvested for germinal center B cell 
analysis. 
 
Flow cytometry 
 
The antibodies used in the flow cytometry analyses were as follows:  anti-mouse 
CD4 (GK1.5), anti-mouse CD8a (53-6.7), anti-mouse B220 (RA2-6B2), anti-mouse TCRβ 
(H57-597), anti-mouse GL7 (GL7), anti-mouse CD38 (90), anti-mouse IgM (RMM-1) and 
anti-mouse IgD (11-26c.2a) were purchased from Biolegend.  The anti-mouse Fas (Jo2) 
antibody was purchased from BD Biosciences. The anti-mouse Ki67 antibody was 
purchased from eBioscience. 7-Aminoactinomycin D (7-AAD) was purchased from Life 
Technologies. 
Single-cell suspensions were prepared from tissue samples and suspended in 
cold FACS buffer (1×PBS supplemented with 5% bovine calf serum).  1×106 cells were 
stained with antibodies in the dark at 4°C for 30 min.  After washing with cold FACS 
buffer, cell suspensions were analyzed on a FACSCanto II flow cytometer (BD 
Biosciences).  FlowJo software (Tree Star) was used for data analysis.  
 
Histology and immunofluorescence 
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Tissue samples were either fixed in 10% formalin or frozen in OCT compound for 
subsequent analysis. For routine histology examination, formalin-fixed samples were 
embedded in paraffin and sectioned, followed by hematoxylin and eosin staining. For 
immunofluorescence studies, 5 μm frozen sections were made and fixed in 50:50 
acetone/methanol at -20℃ for 10 minutes. The sections were then stained with primary 
antibody at 4℃ overnight, followed by secondary antibody staining and Hoechst 33342 
nuclear counter stain (Life Technologies). The slides were mounted in Fluoromount G 
(SouthernBiotech) and examined with a confocal microscope (SP5, Leica). 
 
Real-time PCR 
 
Germinal center B cells (B220+GL7+Fas+) and non-germinal center B cells 
(B220+GL7-Fas-) were sorted from the spleens of NP-CGG/alum immunized mice, and 
their RNA was extracted with RNaqueous micro kit (Life Technologies). The RNA was 
reverse transcribed into cDNA with random hexamers and M-MLV reverse transcriptase 
(Life Technologies). Real-time PCR was performed with a Mastercycler ep realplex 
(Eppendorf). 18s rRNA was used as an internal control. The primer sequences are: Id3-F, 
AGCTTTTGCCACTGACCC; Id3-R, AGATCGAAGCTCATCCATGC; Id3-probe, /56-
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FAM/TCCCAGAGT/ZEN/CCCAGAGTCCCAG/3IABkFQ/; 18s rRNAF, GTT CCT TTG 
GTC GCT CGC TCC TC; 18S rRNAR, GGC ACG GCG ACT ACC ATC GA. 
 
Statistical analysis 
 
The real-time PCR data was compared using Student’s t test, and p value less 
than 0.05 was considered significant. The survival lengths of animals with different 
genotypes were analyzed with Kaplan–Meier survival curves, and different groups were 
compared using the log rank test.  p value less than 0.05 was considered significant. 
4.3 Results 
4.3.1 Id3 is expressed in both germinal center and non-germinal 
center B cells 
I first sought to determine whether Id3 is expressed in B cells during an immune 
response by immunizing both wild type and EμMyc transgenic mice with NP-
CGG/alum i.p. 10 days after the immunization. Similar percentages of GL7+Fas+ cells 
could be detected among the splenic B220+ population in both wild type and EμMyc 
transgenic mice (Fig 18A). I sorted the B220+GL7+Fas+ and B220+GL7-Fas- cells and 
performed real-time PCR to detect Id3 mRNA expression, and I found that Id3 is 
detectable in both populations from either wild type or EμMyc transgenic mice (Fig 18B). 
Overall, the expression level is very similar across all sample groups; the only significant 
difference is between the non-germinal center B cells from wild type versus EμMyc 
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transgenic mice, with the expression being lower in those from the transgenic mice. This 
is different from the studies performed with Burkitt’s lymphoma cell lines; in those 
experiments, Myc appeared to be an inducer of Id3 expression (Seitz et al., 2011). My 
finding demonstrated that malignant cells may behave differently from premalignant 
cells, and in order to truly understand the role of a genetic change in the transformation 
of a cell population, it is very important to develop a mouse model and observe the 
impact of the genetic change early in the disease developmental process. 
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Figure 18: Expression of Id3 among wild type (WT) and EμMyc+ germinal 
center (GC) and non-germinal center (non GC) B cells 10 days after immunization 
with NP-CGG. 
(A) 10 days after immunization, the percentage of GL7+Fas+ germinal center cells among 
splenic B220+ cells was similar between wild type and EμMyc+ mice. Data representative 
of 3 mice in each group. (B) The Id3 mRNA expression level across different groups of B 
cells sorted from the spleen of immunized animals was determined by QPCR. GC: 
GL7+Fas+; non GC: GL7-Fas-. Each dot represents one mouse. 
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4.3.2 Id3+/- EµMyc+ mice succumb to lymphoid tumor faster than Id3+/+ 
EµMyc+ mice, but the tumors have a T cell origin 
After confirming that Id3 is expressed in both germinal and non-germinal center 
B cells in the mouse, I next sought to determine the effect of Id3 deficiency on the mouse 
life span and tumor formation in the context of c-Myc over-expression. When comparing 
the life span between Id3+/- EμMyc+ and Id3+/+ EμMyc+ mice, I found that Id3+/- EμMyc+ 
mice have a reduced survival time (Fig 19) (median survival: 70.5 days for Id3+/- EμMyc+ 
mice vs. 114.0 days for Id3+/+ EμMyc+ mice, log rank test *p=0.01). The Id3+/- EμMyc+ mice 
all die of a lymphoproliferative disease that infiltrates multiple organs including the 
lymph nodes, spleen, liver, kidney and lung. This result indicates that Id3 is a very 
important tumor suppressor in the lymphoid system in the context of c-Myc over-
expression, and loss of only one Id3 allele can greatly accelerate the oncogenesis process. 
Id3+/- EμMyc+ mice rarely survived until reproductive age to enable the production of 
Id3-/- EμMyc+ mice. 
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Figure 19: Loss of one copy of Id3 gene reduced survival time of EμMyc 
transgenic mice 
N=10 for Id3+/- EμMyc+, n=8 for Id3+/+ EμMyc+; log rank test *p=0.01. 
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However, when I analyzed the phenotype of the cancer cells recovered from the 
Id3+/- EμMyc+ mice, I found that these cells were not B cells, but they are TCRβ+ T cells 
(Fig 20). Most cells were CD4+ CD8α+, resembling the double positive (DP) thymocytes. 
In comparison, the cancer cells from Id3+/+ EμMyc+ mice were B cells (Fig 20), as reported 
previously (Adams et al., 1985). It is known that the EμMyc+ transgene can be expressed 
in T cells, and certain mouse strains preferentially develop T cell disease when the 
EμMyc+ transgene is introduced (Yukawa et al., 1989). My result indicates that c-Myc 
over-expressing T cells or T cell progenitors are more prone to cancer development than 
B cells in the C57BL6 genetic background, but Id3 was very efficient in suppressing this 
process, so in Id3+/+ animals the B cell malignancy can develop at a later time point. How 
Id3 suppresses c-Myc-driven oncogenesis in T cells, and whether the mechanism is 
similar or different from that in B cells, will be one objective of our future studies. 
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Figure 20: Id3+/- EμMyc+ mice develop T cell lymphoma 
(A) Comparing cells from a normal lymph node of a wild type mouse to cells from 
tumors of Id3+/+ EμMyc+ mice and Id3+/- EμMyc+ mice. While Id3+/+ EμMyc+ tumor cells 
are mostly B220+ B cells, Id3+/- EμMyc+ tumor cells are TCRβ+ T cells. (B) The B220+ cells 
from Id3+/+ EμMyc+ mice are also IgM+. (C) The TCRβ+ T cells from Id3+/- EμMyc+ mice 
are mostly CD4+CD8α+. Data representative of three mice in each group. 
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4.3.3 Germinal center B cell-specific Id3 knockout, EµMyc+ mice may 
have accelerated B cell lymphoma formation with some Burkitt’s-like 
features 
The above study demonstrated the tumor suppressor role of Id3 in the context of 
c-Myc over-expression in T cells. However, the rapid generation of T cell lymphoma 
prevents further analysis of any possible role of Id3 in the development of Burkitt’s 
lymphoma. Therefore, I switched to a system with more limited and specific deletion of 
Id3, utilizing the Id3f/f AIDCre+ mice. AID (activation-induced cytidine deaminase) is an 
enzyme that is specifically highly expressed in germinal center B cells, the supposed 
origin of human Burkitt’s lymphoma. AIDCre can drive efficient deletion of floxed genes 
in the germinal center B cells (Crouch et al., 2007). Preliminary results showed that the 
Id3f/f AIDCre+ EμMyc+ mice developed B cell, not T cell, lymphoma (Fig 21A). These 
tumors do show some features similar to human Burkitt’s lymphoma, such as a 
histology feature called “starry sky”, indicating rapid proliferation of tumor cells and 
spontaneous apoptosis (Fig 21B). Immunofluorescence staining showed that nearly 
100% of cells express Ki-67, a marker for cells actively going through cell cycles (Fig 
21C). Flow cytometry also showed that they express some markers comparable to 
germinal center B cells (Fig 21A). Whether the Id3f/f AIDCre+ EμMyc+ mice have a shorter 
life span than the Id3f/f AIDCre- EμMyc+ mice cannot be concluded until we accumulate 
more survival data. 
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Figure 21: Tumor cells from Id3f/f AIDCre+ EμMyc+ mice show features of 
germinal center B cells 
(A) The tumor cells from Id3f/f AIDCre+ EμMyc+ mice are mostly B220+ B cells. A large 
proportion of these cells is IgM-IgD-, and they express lower levels of CD38 (line 
histogram) comparing to B cells from a wild type mouse spleen (gray shaded histogram), 
characteristic of germinal center B cells. (B) Hematoxylin & eosin staining of the tumor 
tissue showed a “starry sky” pattern. (C) Immunofluorescence staining showed that the 
tumor tissue (right) is strongly positive of Ki67, as compared to the low level staining of 
normal lymph node tissue from a wild type mouse (left). Red: anti-Ki67. Blue: Hoechst 
33342. 
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4.4 Discussion 
Our study demonstrated that Id3 indeed can function as a tumor suppressor in 
the lymphoid system in the context of c-Myc over-expression, at least in the T cell 
lineage. When Id3 is specifically deleted in the germinal center B cells, EμMyc transgenic 
mice can indeed develop a Burkitt’s-like B cell disease. This result is compatible with the 
previous human Burkitt’s lymphoma sequencing studies and the Burkitt’s lymphoma 
cell line studies. 
In order to further confirm that Id3 deficiency potentiate the development of 
Burkitt’s-like disease in the mouse, we need to collect more animals to establish a 
survival difference between Id3f/f AIDCre+ EμMyc+ mice and Id3f/f AIDCre- EμMyc+ mice. 
We need to examine more features of germinal center B cells, such as Bcl6 expression 
(Basso and Dalla-Favera, 2012), to determine whether the cancer cells truly have a 
germinal center origin, as Bcl6 is considered the master transcriptional factor of germinal 
center B cells as well as a hallmark of Burkitt’s lymphoma. So far, limited analysis with 
other classical mouse germinal center markers, such as GL7 and Fas, revealed that some 
tumor cells show a general increase of both markers but below the levels seen in wild 
type germinal centers, while other tumors contain a fraction of cells expressing only Fas 
or GL7 (data not shown). It is known that tumor cells sometimes do not retain all of the 
surface markers of their cells of origin (Longo, 2011); a standardized panel of germinal 
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center specific/related markers will be required to best describe the identity of these 
tumor cells arising in the Id3 conditional knockout, EμMyc+ mice. 
In addition to surface markers and transcription factors, two other important 
pieces of evidence of germinal center history will be immunoglobulin isotype switching 
and somatic hypermutation. We plan to perform more flow cytometry analysis of tumor 
cells to detect any product of isotype class switching, such as surface IgG or IgA 
expression. We will also sequence the immunoglobulin genes of the tumor cells, 
comparing them to germline sequences to detect evidence of somatic hypermutation. 
Although analysis of wild type and EμMyc transgenic mice did not show 
significant difference in Id3 expression between germinal center B cells and non-
germinal center B cells, Id3 expression is still detected in the germinal center, and 
specific deletion of Id3 in germinal center B cells may perturb normal GC responses. We 
will try to induce germinal center responses in Id3f/f AIDCre+ EμMyc+ mice and Id3f/f 
AIDCre- EμMyc+ mice to determine if the absence of Id3 results in any advantage for the 
germinal center population prior to malignant transformation. These results will help us 
clarify how Id3 cooperates with c-Myc in transforming B lymphocytes. 
In order to compare our model with human Burkitt’s lymphoma and determine 
how similar this model is to human disease, we will perform whole exome sequencing 
and RNA sequencing to obtain the mutation and gene expression profile of the tumor 
cells from Id3f/f AIDCre+ EμMyc+ mice. These methods have been used previously to 
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validate another mouse model of Burkitt’s lymphoma (Sander et al., 2012). If our model 
can be shown to closely resemble human Burkitt’s lymphoma, it can potentially be a 
better model since it captures two of the most common genetic drivers of the disease: 
Myc over-expression and Id3 loss. The model may be useful for further dissecting the 
oncogenesis mechanisms as well as testing experimental therapies. Comparing this 
model with other tumor models associated with loss or gain of E proteins/Id proteins 
may also inform us how the same genes can switch between the role of oncogenes and 
tumor suppressor genes in different tissue and developmental stages. 
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5. General discussions and future directions 
Through these three projects we have once again demonstrated the versatility of 
the E – Id gene regulation network. The same Id2 protein can inhibit the survival of γδT 
cells during development but sustain the survival of CD4 T cells during an immune 
response. The same E2A protein can inhibit T cell lymphoma development in the wild 
type mice but may be promoting T cell lymphoma development in the context of c-Myc 
over-expression. These apparently contradictory functions of the same genes naturally 
lead us to ask the next question: how can this be achieved at the molecular level? 
There are several possible mechanisms. First, E proteins may be regulating 
different sets of genes and pathways in different cells at different developmental stages 
(Lin et al., 2012a). Epigenomic modifications and chromatin accessibility differences may 
dictate which E-box containing gene is susceptible to E protein regulation in a particular 
cell type. Second, some genes may be regulated by E proteins in a similar manner across 
cell types, but different cell types have different reliance on each gene, so the net 
outcome becomes different. For example, E proteins may up-regulate one anti-apoptotic 
gene (such as Bcl-2 (Cannarile et al., 2006)) but also up-regulate another pro-apoptotic 
gene (such as Bim (Schwartz et al., 2006)); the cells that depend on the first gene will 
experience a survival advantage when E protein activity is high, but the cells that are 
sensitive to the second will experience increased apoptosis. Third, although there are no 
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such examples reported yet, theoretically E proteins may bind to the same target genes 
across several cell types but up-regulate the genes in some cells while down-regulate 
them in others, through recruiting different transcription co-activators or co-repressors. 
Although the E protein binding to the target DNA sequence may be the same, the co-
repressor (such as ETO (Zhang et al., 2004)) or co-activator (such as p300 (Qiu et al., 
1998)) available in the cell may be different, thus resulting in opposite effects on the 
expression of the target genes. 
To differentiate among these three possibilities, we may turn to the new high 
throughput chromatin immunoprecipitation-sequencing (ChIP-Seq) method to examine 
the activity of E proteins in different situations (Lin et al., 2012a). By recording the 
position of E proteins in the entire genome, we will understand whether it is regulating 
different genes and pathways in different cell types. Combining the ChIP-Seq data with 
gene expression profiling methods such as microarray or RNA-Seq, we may deduct 
whether E proteins are up-regulating or down-regulating one particular set of genes, 
and whether its effect is the same or different in different cell types. This research 
method will be particularly powerful in the study of phenomena that appears to be “fine 
tuned” by E protein activity levels, such as the development of Vγ1.1+Vδ6.3+ T cells 
discussed in Chapter 2, or the selective expansion of NKT cells versus Vγ1.1+Vδ6.3+ T 
cells in Id2f/f Id3f/f LckCre+ mice with wild type or partially deleted E protein genes (Li et 
al., 2013). In these cases, the molecular difference is subtle; E protein activity may be 
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moderately higher in one situation than in another, yet the result can be dramatically 
different. Do E proteins bind to loci normally not easily accessible in the cell only when 
there is an E protein excess? Do they influence the expression of some genes to a greater 
extent than others when the E protein activity is higher? Can we predict such difference 
by analyzing the sequences adjacent to the E-box binding site, also inferring potential 
partners of E proteins in the process? Analyzing the genome-wide localization of E 
proteins and the expression of genes bound by E proteins can help us find clues to 
answer these questions. 
On the side of the Id proteins, the situation initially appears to be simple. No 
matter whether the cell expresses Id2 or Id3, the result may be the same: E protein 
activity will be inhibited. However, evolution nevertheless created two Id proteins to be 
expressed in the mammalian immune system, and two other homologs (Id1, Id4) exist 
and are expressed in other tissues. In my study, I described many different functions 
that are carried out by Id2 or Id3, respectively: (1) Id3 plays a dominant role in limiting 
the expansion of Vγ1.1+Vδ6.3+ cells, while Id2 plays a moderate role in limiting 
maturation of γδ T cells in general; (2) Id2 sustains the effector cell population of CD4 T 
cells, and its role cannot be compensated by Id3. In previous reports, Id2 and Id3 have 
also been shown to control different populations of memory CD8 T cells (Yang et al., 
2011); (3) while both Id2 and Id3 are expressed in the germinal center B cells, with Id2 
being highly expressed (Schmitz et al., 2012), only Id3 mutation was detected in the 
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germinal center B cell-derived Burkitt’s lymphoma. As previously described, all the 
innate lymphoid cells, including natural killer cells (NK), lymphoid tissue inducer cells, 
and a variety of cytokine producing, helper T cell-like innate lymphoid cells, depend on 
Id2 for their development, not Id3(Mjosberg et al., 2012). It was only in the development 
of SP thymocytes from DP thymocytes, and in the development of NKT cells, that a 
mutually compensating relationship between Id2 and Id3 has been clearly demonstrated, 
since only double conditional knockouts of both genes show a significant phenotype 
(Jones-Mason et al., 2012; Li et al., 2013). How and why does the organism use two or 
more Id proteins to regulate E proteins to achieve these different effects? 
Gene expression analysis showed that the mRNA level of Id2 and Id3 are 
different in many cell types of the immune system (Fig 22). This different expression 
pattern may directly explain part of the functional difference between the two genes. For 
example, Id2 is highly expressed in the NK cells while Id3 is not, thus explaining the 
phenomenon that NK cells require Id2 but not Id3 for their development. The cis-
regulatory elements in the DNA sequence that determine this differential expression 
pattern remains to be discovered.  
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Figure 22: Relative expression of Id2 and Id3 mRNA in major cell types of the 
immune system 
Data obtained from the Immunological Genome Project website 
(https://www.immgen.org/) 
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In addition to difference in mRNA expression levels, the 3’untranslated regions 
(UTRs) of the Id2 and Id3 mRNAs also show significant differences (Fig 23), suggesting 
possible differences in post-transcriptional regulations. Analysis of potential microRNA 
recognition site on the 3’UTRs showed no conservation between the two genes, 
indicating that they may respond very differently to RNA interference control. Some of 
my in vitro preliminary experiments showed that the 3’UTR of Id3 indeed has the ability 
to reduce luciferase protein expression when attached to the luciferase mRNA (data not 
shown). The effect appeared to be mediated by microRNA regulation; therefore, this is 
very unlikely to be shared between Id2 and Id3. This shows yet another layer of 
regulation different cell types may utilize to control the two Id genes separately. 
Finally, at the protein level, the two Ids also have some important differences 
(Fig 24). Their dimerization interface sequences in the helix-loop-helix domain, although 
highly similar, still show some amino acid sequence discrepancies, suggesting that they 
may have different binding affinity with different E proteins. Id2 also contains one 
nuclear export signal domain that is not present in Id3, which may influence its 
intracellular localization and its access to the target E proteins.  
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Figure 23: Alignment of Id2 and Id3 3’UTR sequences 
Star (*) indicates identical sequence; colon (:) and period (.) indicate mismatches; dash (-) 
indicates insertion or deletion. Underlined sequence indicates predicted microRNA 
binding regions. Notice that no predicted microRNA binding site is shared between Id2 
and Id3. Alignment generated by ClustalW2 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/). MicroRNA binding predicted by 
microRNA.org (http://www.microrna.org/). 
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Figure 24: Alignment of Id2 and Id3 protein sequences 
Star (*) indicates identical sequence; colon (:) and period (.) indicate mismatch but 
chemically similar residues; dash (-) indicates insertion or deletion. The underlined Id2 
amino acid sequence 38-79 forms the dimerization interface in its helix-loop-helix 
domain, which is very similar but not identical to the corresponding sequence in Id3. Id2 
amino acid sequence 106-115 is an identified nuclear export signal, which is absent in 
Id3. Alignment generated by ClustalW2 (http://www.ebi.ac.uk/Tools/msa/clustalw2/). 
Domain information obtained from NCBI database (http://www.ncbi.nlm.nih.gov/). 
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In summary, Id2 and Id3 have diverged in every aspect from gene expression to 
protein sequence and appear to have evolved to play different functions for a long time. 
Although in the beginning, these Id genes may have arisen through gene duplication to 
serve the kind of “dual safety” mechanisms as described in chapter 2 of this thesis, as 
time went on, they progressively picked up more and more mutations or variations and 
became more versatile to execute functions unique to each gene. This phenomenon 
reminds us that whenever we study genes within a multi-member family, we should 
always survey both the similarity and diversity of the family members. 
Through our studies, we attempt to understand the role of E proteins and Id 
proteins in order to better understand how the immune system works, in the hope of 
generating useful knowledge to improve human health. Our attempt to build a mouse 
Burkitt’s lymphoma model based on observed human genetic changes is clearly a direct 
effort in this direction. The genetically modified mouse models built in this way have 
advantages compared with those traditional mouse models of human diseases induced 
by chemical treatment or those arising spontaneously without specified genetic changes. 
Because the models we study share characteristic genetic changes with human patients, 
the pathobiology we learn from them may be more applicable to human. However, one 
must still be cautious because even though we engineer one or two key genetic changes 
into the mouse and can produce a similar disease phenotype, true human diseases are 
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still more heterogeneous, and other minor genes might be involved in the pathogenesis 
process. Nevertheless, as the knowledge of the genetic landscape of different human 
diseases increase, and our capability of simultaneously manipulating multiple genes in 
the animal models increases, this approach will lead to more and more realistic animal 
models in the future. 
However, oftentimes original observations made in the mouse cannot be 
translated to human. For example, although our lab found that Id3 knockout mice 
spontaneously develop Sjogren syndrome (Li et al., 2004), Id3 mutation has not been 
identified in human Sjogren syndrome patients (Sellam et al., 2008), leading to some 
doubt about the relevance of this mouse model to human diseases. I believe we should 
not be discouraged from studying the Id3 knockout Sjogren syndrome model or other 
mouse models just because of these negative reports. First, despite all the discrepancies, 
human biology and mouse biology still share a great amount of similarities; the mouse 
model remains the best available experiment model for scientists to ask a large number 
of questions within a reasonable budget. Second, I believe more successful translation of 
mouse research requires a much more precise comparison between the two species, 
targeting the right patient population and the right cell population. In our Burkitt’s 
lymphoma mouse study, we found that deleting Id3 in all mouse cells combined with c-
Myc over-expression did not lead to B cell lymphomas but led to T cell lymphomas. 
When we limited the deletion to germinal center B cells, we observed tumors of B cell 
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origin that is more similar to human Burkitt’s lymphomas. The same selectivity should 
be essential when trying to translate the research in the opposite direction. It is possible 
that Id3 may be involved in the pathogenesis of a subset of human Sjogren syndrome. 
This disease is impressively diverse and has several primary and secondary forms, and 
failing to detect Id3 mutation in a general patient population does not rule out its role in 
any subsets. Moreover, Id3 mutation, or down-regulation, most likely occurs only in the 
effector immune cells infiltrating the patients gland tissues, since germline deletion of 
Id3 may have multiple effects, and humans with complete loss of Id3 may not survive. 
Like many mutations or other genetic changes occurring in tumor cells, these changes 
are most likely somatic, so sequencing the germline DNA is unlikely to detect them. 
Fortunately, with the progress of modern sequencing technology, we are now 
increasingly capable of accurately categorizing patients with apparently similar diseases 
into mechanistically distinct groups, using smaller and smaller amount of tissue samples. 
Comparing the phenotype between animal models and human patient groups may 
allow us eventually to identify the correct relationship between the two.  
Even if there is genuinely no direct counterparts between human and mouse in 
terms of certain gene-disease relationship, very likely they may still share common 
downstream disease evolution mechanisms. For example, various mouse models of 
lupus-like diseases are induced by different genetic modifications, but they all share the 
production of autoantibodies and several lupus-like end organ damages, such as 
 113 
glomerulonephritis. Even though Id3 mutations have not yet been identified in human 
Sjogren syndrome patients, they do share the features of exocrine gland infiltration and 
fibrosis with the Id3 knockout mouse models. The mechanisms involved in these 
processes, such as the excessive production of IL-13 observed in mice (Mahlios and 
Zhuang, 2011), may also occur in human, even though it might be triggered by a genetic 
change other than Id3 mutation. If this is proven to be the case, anti-IL13 therapy may 
well benefit patients with Sjogren syndrome. The translation of finding the role of IL-17 
in psoriasis development in mouse models (Cai et al., 2011) into successful anti-IL-17 
treatment for psoriasis patients (Leonardi et al., 2012; Papp et al., 2012) is a great 
example; although human psoriasis certainly is not induced by the same chemical as in 
certain mouse model (Cai et al., 2011), therapies targeting the same pathway benefits 
both. I will always keep this, and all what I have learned through the studies of E 
proteins and Id proteins, in mind to serve as my permanent motivation for future 
scientific researches. 
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